Aflibercept Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 14, 2026

The clinical evidence base for Aflibercept comprises 594 peer-reviewed publications across 15 journals, 82 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Macular Degeneration, Diabetic Retinopathy, Macular Edema, and Wet Macular Degeneration. Most recent publication: Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study., Ophthalmol Ther, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Wykoff CC, Brown DM, Reed K, et al. · JAMA Ophthalmol · 2023
PubMed: PMID 37535382 · NCT06683950 · Macular Degeneration
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF, Fizazi K, Ivanov S, et al. · Lancet Oncol · 2013
PubMed: PMID 23742877 · NCT00519285 (VENICE) · Neoplasm Metastasis
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
Scott IU, VanVeldhuisen PC, Ip MS, et al. · JAMA · 2017
PubMed: PMID 28492910 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lanzetta P, Korobelnik JF, Heier JS, et al. · Lancet · 2024
PubMed: PMID 38461841 · NCT06683950 · Macular Degeneration
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet · 1998
PubMed: PMID 9742976 · NCT02556723 · Macular Degeneration
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. · N Engl J Med · 2015
PubMed: PMID 25692915 · NCT01627249 (Protocol T)
Diseases of the retina.
D'Amico DJ · N Engl J Med · 1994
PubMed: PMID 8208273 · NCT02291887 · Macular Degeneration
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
Baker CW, Glassman AR, Beaulieu WT, et al. · JAMA · 2019
PubMed: PMID 31037289 · NCT01909791 (Protocol V)

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

Trial	Indication	Primary endpoint	Arm	Value
NCT00327444	Ovarian Neoplasms	Time to Repeat Paracentesis (TRP) From Day 1 up to 6 months from randomization	Aflibercept	55.1 days (±7.25 Standard Error)
NCT00327444	Ovarian Neoplasms		Placebo	23.3 days (±7.70 Standard Error)
NCT00509795 VIEW1	Macular Degeneration	Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) Baseline and at week 52	IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4	95.9 percentage of patients
			IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4	95.1 percentage of patients
			IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8	95.1 percentage of patients
			Ranibizumab 0.5mg Q4	94.4 percentage of patients
			Total	95.1 percentage of patients
NCT00519285 VENICE	Neoplasm Metastasis	Overall Survival Time From randomization up to the cut-off date (median follow-up of 35.4 months)	Aflibercept	22.14 months
NCT00519285 VENICE	Neoplasm Metastasis		Placebo	21.22 months
NCT00532155 VITAL	Lung Neoplasms	Overall Survival (OS) Baseline to the date when 687 deaths occurred (26 January 2011)	Aflibercept/Docetaxel	10.05 months
NCT00532155 VITAL	Lung Neoplasms		Placebo/Docetaxel	10.41 months
NCT00561470 VELOUR	Colorectal Neoplasms	Overall Survival (OS) From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)	Aflibercept/FOLFIRI	13.50 months
NCT00561470 VELOUR	Colorectal Neoplasms		Placebo/FOLFIRI	12.06 months
NCT00574275 VANILLA	Pancreatic Neoplasms	Overall Survival (OS) From the first randomization until the end of study data cutoff date (approximately 2 years)	Aflibercept and Gemcitabine	6.54 months
NCT00574275 VANILLA	Pancreatic Neoplasms		Placebo and Gemcitabine	7.75 months
NCT00637377 VIEW 2	Macular Degeneration	Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) At week 52	Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4	96.27 Percentage of participants
			Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4	95.62 Percentage of participants
			Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8	95.56 Percentage of participants
			Ranibizumab 0.5mg Q4	94.42 Percentage of participants
NCT00964795	Macular Degeneration	Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD Baseline (day 1) through end of treatment (Week 180)	Open-label Intravitreal Aflibercept Injection	239 participants
			Open-label Intravitreal Aflibercept Injection	204 participants
			Open-label Intravitreal Aflibercept Injection	290 participants
			Open-label Intravitreal Aflibercept Injection	17 participants
			Open-label Intravitreal Aflibercept Injection	12 participants
			Open-label Intravitreal Aflibercept Injection	105 participants
			Open-label Intravitreal Aflibercept Injection	232 participants
			Open-label Intravitreal Aflibercept Injection	169 participants
NCT01012973 GALILEO	Macular Edema	Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures Baseline and Week 24	Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)	60.2 Percentage of participants
NCT01012973 GALILEO	Macular Edema		Sham Treatment	22.1 Percentage of participants
NCT01363440 VISTA DME	Diabetic Retinopathy	Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF) Baseline and Week 52	Control	.10 letters correctly read (±1.03 Standard Error)
			Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4	12.3 letters correctly read (±.76 Standard Error)
			Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8	10.6 letters correctly read (±.69 Standard Error)
NCT01482910	Macular Degeneration	Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF) Baseline and at week 28	Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)	14.0 Letters correctly read (±12.1 Standard Deviation)
NCT01482910	Macular Degeneration		PDT Treatments	3.9 Letters correctly read (±14.6 Standard Deviation)
NCT01521559 VIBRANT	Retinal Vein Occlusion	Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF Baseline to week 24	Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)	48 participants
NCT01521559 VIBRANT	Retinal Vein Occlusion		Macular Laser Photocoagulation Treatment (Control)	24 participants
NCT01571284	—	Creatinine Clearance of Aflibercept Plus FOLFIRI Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	71.4 mL/min (±29.3 Standard Deviation)
NCT01571284	—	Number of Participants With Abnormal Electrolytes Parameters Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	52 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	32 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	213 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	5 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	166 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	16 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	121 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	10 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	75 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	181 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	1 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	2 Participants
NCT01571284	—	Number of Participants With Abnormal Hematological Parameters Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	532 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	72 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	450 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	13 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	293 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	14 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	535 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	227 Participants
NCT01571284	—	Number of Participants With Abnormal Non-Gradable Biochemistry Parameters Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	83 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	60 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	250 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	77 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	79 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	423 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	135 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	41 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	162 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	217 Participants
NCT01571284	—	Number of Participants With Abnormal Renal and Liver Function Parameters Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	465 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	342 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	9 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	10 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	130 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	2 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	270 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	161 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	12 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	23 Participants
NCT01571284	—	Number of Participants With Cycle Delay and/or Dose Modification Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	97 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	43 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	5 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	308 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	39 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	163 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	660 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	119 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	5 Participants
NCT01571284	—	Number of Participants With International Normalized Ratio (INR) Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	2 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	106 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	0 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	2 Participants
NCT01571284	—	Number of Participants With Other Abnormal Biochemistry Parameters Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	90 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	6 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	6 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	241 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	30 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	403 Participants
NCT01571284	—	Number of Participants With Proteinuria (Grade>=2) Concomitant With Hematuria and /or Hypertension Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	72 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	3 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	4 Participants
NCT01571284	—	Number of Participants With Proteinuria Events Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	286 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	5 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	123 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	54 Participants
NCT01571284	—	Number of Participants With Proteinuria Grade >=2 Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	182 participants
NCT01571284	—	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	272 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	104 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	208 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	47 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	159 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	609 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	769 Participants
NCT01571284	—	Number of Participants With Urinary Protein-Creatinine Ratio (UPCR) Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	265 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	27 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	24 Participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	51 Participants
NCT01627249 Protocol T	—	Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score <69 Baseline to 1-year	Aflibercept	18.9 units on a scale (±11.5 Standard Deviation)
			Bevacizumab	11.8 units on a scale (±12.0 Standard Deviation)
			Ranibizumab	14.2 units on a scale (±10.6 Standard Deviation)
NCT01627249 Protocol T	—	Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score 78-69 Baseline to 1-year	Aflibercept	8.0 units on a scale (±7.6 Standard Deviation)
			Bevacizumab	7.5 units on a scale (±7.4 Standard Deviation)
			Ranibizumab	8.3 units on a scale (±6.8 Standard Deviation)
NCT01627249 Protocol T	—	Overall Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year Baseline to 1-year	Aflibercept	13.3 units on a scale (±11.1 Standard Deviation)
			Bevacizumab	9.7 units on a scale (±10.1 Standard Deviation)
			Ranibizumab	11.2 units on a scale (±9.4 Standard Deviation)
NCT01661270 AFLAME	—	Progression-free Survival (PFS) 26.7 months	Aflibercept	6.93 months
NCT01661270 AFLAME	—	Progression-free Survival (PFS) 26.7 months	Placebo	5.59 months
NCT01670721 AFEQT	—	Percentage of Participants With Adverse Events (AEs) Baseline upto 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure:723 days)	Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	100.00 Percentage of participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	21.1 Percentage of participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	16.0 Percentage of participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	23.4 Percentage of participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	9.1 Percentage of participants
			Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)	40.6 Percentage of participants
NCT01783886 VIVID EAST	Macular Edema	Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF) Baseline up to week 52	Intravitreal Aflibercept Injection 2Q4	13.7 Letters correctly read (±8.4 Standard Deviation)
			Intravitreal Aflibercept Injection 2Q8	12.8 Letters correctly read (±9.5 Standard Deviation)
			Macular Laser Photocoagulation	-0.2 Letters correctly read (±13.5 Standard Deviation)
NCT01909791 Protocol V	—	Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline 2 years	Initiation With Aflibercept	33 Eyes
			Initiation With Laser Photocoagulation	36 Eyes
			Initiation With Observation	39 Eyes
NCT01940887	Macular Degeneration	Mean Change in Visual Acuity (Measured at Baseline and at the Month 12 Visit) 12 months	E10030 + Bevacizumab or Aflibercept	9.42 letters (±0.85 Standard Error)
NCT01940887	Macular Degeneration		Sham + Bevacizumab or Aflibercept	9.04 letters (±0.85 Standard Error)
NCT01969708 SCORE2	Retinal Vein Occlusion	Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 Month 0 to 6	Aflibercept	18.9 letters read
NCT01969708 SCORE2	Retinal Vein Occlusion		Bevacizumab	18.6 letters read
NCT02307682 HAWK	Choroidal Neovascularization	Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye Baseline, Week 48	Aflibercept 2 mg	7.0 letters (±13.16 Standard Deviation)
			Brolucizumab 3 mg	5.9 letters (±13.49 Standard Deviation)
			Brolucizumab 6 mg	6.4 letters (±14.40 Standard Deviation)
NCT02396316 VEGA	Glaucoma, Neovascular	Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1 From baseline to pre-dose at Week 1	Aflibercept 2 mg Intravitreal (IVT) Injection Group	-8.5 mmHg (±8.7 Standard Deviation)
NCT02396316 VEGA	Glaucoma, Neovascular		Sham Injection Group	-4.9 mmHg (±10.8 Standard Deviation)
NCT02434328 HARRIER	Choroidal Neovascularization	Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye Baseline, Week 48	Aflibercept 2 mg	7.6 letters (±12.47 Standard Deviation)
NCT02434328 HARRIER	Choroidal Neovascularization		Brolucizumab 6 mg	6.9 letters (±11.47 Standard Deviation)
NCT02540954	Macular Degeneration	Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye From baseline to Week 52	Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)	-0.5 Letters read correctly (±8.4 Standard Deviation)
NCT02540954	Macular Degeneration		Aflibercept Extended Dosing	-0.3 Letters read correctly (±7.5 Standard Deviation)
NCT02634333	Diabetic Retinopathy	Change in Visual Acuity From Baseline 2 years	Aflibercept	-0.9 Letter Score (±5.8 Standard Deviation)
			Aflibercept	-2.7 Letter Score (±6.5 Standard Deviation)
			Sham	-2.4 Letter Score (±5.8 Standard Deviation)
			Sham	-2.0 Letter Score (±6.1 Standard Deviation)
NCT02634333	Diabetic Retinopathy	Development of PDR and/or DME (Whichever Came First) 2 years	Aflibercept	27 Eyes
			Aflibercept	54 Eyes
			Sham	97 Eyes
			Sham	75 Eyes
NCT02718326 PANORAMA	—	Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 Groups At Week 24	IAI 2 mg Groups Combined (2Q16 & 2Q8)	58.4 Percentage of participants
			Intravitreal Aflibercept Injection (IAI) 2Q16	61.5 Percentage of participants
			Intravitreal Aflibercept Injection (IAI) 2Q8	55.2 Percentage of participants
			Sham Treatment	6.0 Percentage of participants
NCT02718326 PANORAMA	—	Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline At Week 52	Intravitreal Aflibercept Injection (IAI) 2Q16	65.2 Percentage of participants
			Intravitreal Aflibercept Injection (IAI) 2Q8	79.9 Percentage of participants
			Sham Treatment	15.0 Percentage of participants
NCT02818998 VIOLET	Macular Edema	Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52 From baseline to Week 52	Aflibercept 2 mg Extended	0.5 Scores on a scale (±6.7 Standard Deviation)
			Aflibercept 2 mg Fixed	0.4 Scores on a scale (±6.7 Standard Deviation)
			Aflibercept 2 mg PRN	1.7 Scores on a scale (±6.8 Standard Deviation)
NCT02858076 AB	Vitreous Hemorrhage	E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) 24 weeks	Intravitreous 2 mg Aflibercept Injections	68.7 units on a scale (±15.0 Standard Deviation)
			Intravitreous 2 mg Aflibercept Injections	59.3 units on a scale (±21.9 Standard Deviation)
			Prompt Vitrectomy Plus Panretinal Photocoagulation	70.0 units on a scale (±18.8 Standard Deviation)
			Prompt Vitrectomy Plus Panretinal Photocoagulation	63.0 units on a scale (±21.7 Standard Deviation)
NCT02980874 SAPPHIRE	Macular Edema	Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) 2 months	Active	114 Participants
NCT02980874 SAPPHIRE	Macular Edema		Control	127 Participants
NCT03321513 DRCR AC	—	Mean Change in Visual Acuity 2 years	Aflibercept- Monotherapy Group	15 Letter Score (±8.5 Standard Deviation)
NCT03321513 DRCR AC	—	Mean Change in Visual Acuity 2 years	Bevacizumab-First Group	14 Letter Score (±8.8 Standard Deviation)
NCT03386474	—	Number of Participants With Ocular and Non-Ocular Treatment Emergent Adverse Events Up to Week 24	Brolucizumab - Overall Extension Study	20 Participants
			Brolucizumab - Overall Extension Study	51 Participants
			Brolucizumab Overall Last 6 Months From Core Study	25 Participants
			Brolucizumab Overall Last 6 Months From Core Study	50 Participants
NCT03481634 KESTREL	Diabetic Retinopathy	Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 Baseline, Week 52	Aflibercept 2 mg	10.6 Scores on a scale (±0.67 Standard Error)
			Aflibercept 2 mg	10.5 Scores on a scale (±0.57 Standard Error)
			Brolucizumab 3 mg	7.3 Scores on a scale (±0.66 Standard Error)
			Brolucizumab 6 mg	9.2 Scores on a scale (±0.57 Standard Error)
NCT03481660 KITE	—	Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 for the Study Eye Baseline, Week 52	Aflibercept 2 mg	9.4 Scores on a scale
NCT03481660 KITE	—		Brolucizumab 6 mg	10.6 Scores on a scale
NCT03622580	—	Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations From Baseline through Week 56	A: Faricimab 6 mg Q8W	10.7 ETDRS Letters
			A: Faricimab 6 mg Q8W	10.6 ETDRS Letters
			B: Faricimab 6 mg PTI	11.6 ETDRS Letters
			B: Faricimab 6 mg PTI	11.4 ETDRS Letters
			C: Aflibercept 2 mg Q8W	11.3 ETDRS Letters
			C: Aflibercept 2 mg Q8W	10.9 ETDRS Letters
NCT03622593 RHINE	—	Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations From Baseline through Week 56	A: Faricimab 6 mg Q8W	11.7 ETDRS Letters
			A: Faricimab 6 mg Q8W	11.8 ETDRS Letters
			B: Faricimab 6 mg PTI	10.8 ETDRS Letters
			B: Faricimab 6 mg PTI	11.2 ETDRS Letters
			C: Aflibercept 2 mg Q8W	10.3 ETDRS Letters
			C: Aflibercept 2 mg Q8W	10.5 ETDRS Letters
NCT03639675 VENERA	Glaucoma, Neovascular	Change in Intraocular Pressure (IOP) From Baseline to Week 1 Baseline and week 1	Aflibercept 2 mg Intravitreal (IVT) Injection Group	-8.3 mmHg (±7.3 Standard Deviation)
NCT03710564 MERLIN	Macular Degeneration	Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Week 52 Baseline, week 52	Aflibercept	0.9 Score on a scale (±6.51 Standard Deviation)
NCT03710564 MERLIN	Macular Degeneration		Brolucizumab	0.3 Score on a scale (±9.02 Standard Deviation)
NCT03802630 RAPTOR	Macular Edema	Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 24 Baseline, Week 24	Aflibercept 2 mg	15.0 Letters read (±0.71 Standard Error)
NCT03802630 RAPTOR	Macular Edema		Brolucizumab 6 mg	13.1 Letters read (±0.71 Standard Error)
NCT03810313 RAVEN	Macular Edema	Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 24 Baseline, Week 24	Aflibercept 2 mg	16.0 Letters read (±0.85 Standard Error)
NCT03810313 RAVEN	Macular Edema		Brolucizumab 6 mg	13.2 Letters read (±0.85 Standard Error)
NCT03823287	Wet Macular Degeneration	Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 From Baseline through Week 48	Arm A: Faricimab	5.8 ETDRS Letters
NCT03823287	Wet Macular Degeneration		Arm B: Aflibercept	5.1 ETDRS Letters
NCT03823300	Wet Macular Degeneration	Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 From Baseline through Week 48	Arm A: Faricimab	6.6 ETDRS Letters
NCT03823300	Wet Macular Degeneration		Arm B: Aflibercept	6.6 ETDRS Letters
NCT03917472 KINGFISHER	Diabetic Retinopathy	Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 Baseline, Week 52	Aflibercept 2mg q4w	11.0 Scores on a scale
NCT03917472 KINGFISHER	Diabetic Retinopathy		Brolucizumab 6mg q4w	12.2 Scores on a scale
NCT04004208 FIREFLEYE	Retinopathy of Prematurity	Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes At 24 weeks after starting study treatment	Aflibercept 0.4 mg	0.855 Proportion of participants
NCT04004208 FIREFLEYE	Retinopathy of Prematurity		Laser Photocoagulation	0.821 Proportion of participants
NCT04005352 TALON	Macular Degeneration	Average Change From Baseline at Week 28 and Week 32 in Best-corrected Visual Acuity (BCVA) - Study Eye Baseline, Week 28 and Week 32	Aflibercept 2 mg	5.1 Scores on a scale (±0.51 Standard Error)
NCT04005352 TALON	Macular Degeneration		Brolucizumab 6 mg	5.2 Scores on a scale (±0.51 Standard Error)
NCT04005352 TALON	Macular Degeneration	Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye Up to Week 32	Aflibercept 2 mg	148 Participants
			Aflibercept 2 mg	147 Participants
			Aflibercept 2 mg	73 Participants
			Brolucizumab 6 mg	141 Participants
			Brolucizumab 6 mg	94 Participants
			Brolucizumab 6 mg	131 Participants
NCT04047472	Macular Degeneration	Change From Baseline at Week 48 in Best-Corrected Visual Acuity in Study Eye Baseline, Week 48	Aflibercept 2 mg	10.9 Letters Read (±0.82 Standard Error)
NCT04047472	Macular Degeneration		Brolucizumab 6 mg	9.9 Letters Read (±0.82 Standard Error)
NCT04049266 DAZZLE	Macular Degeneration	Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48 and 52, Full Analysis Set Year 1 Year 1	Aflibercept 2 mg Q8W	7 ETDRS Letters (±0.77 Standard Error)
NCT04049266 DAZZLE	Macular Degeneration		KSI-301 5 mg Q12W-Q20W	1 ETDRS Letters (±0.78 Standard Error)
NCT04058067 KINGLET	Diabetic Retinopathy	Best-corrected Visual Acuity (BCVA) - Average Change From Baseline Over the Period Week 40 Through Week 52 for the Study Eye Week 40 to Week 52	Aflibercept 2 mg	12.0 Scores on a scale (±0.82 Standard Error)
NCT04058067 KINGLET	Diabetic Retinopathy		Brolucizumab 6 mg	10.1 Scores on a scale (±0.81 Standard Error)
NCT04058067 KINGLET	Diabetic Retinopathy	Change From Baseline at Week 52 in Best-corrected Visual Acuity (BCVA) for the Study Eye. Baseline to Week 52	Aflibercept 2 mg	11.9 Scores on a scale (±0.85 Standard Error)
NCT04058067 KINGLET	Diabetic Retinopathy		Brolucizumab 6 mg	10.6 Scores on a scale (±0.85 Standard Error)
NCT04101721 BUTTERFLEYE	Retinopathy of Prematurity	Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age Baseline to week 52 of chronological age	Aflibercept 0.4 mg	79.6 Percentage of participants
NCT04101721 BUTTERFLEYE	Retinopathy of Prematurity		Laser Photocoagulation	77.8 Percentage of participants
NCT04270747	Macular Degeneration	Mean Change From Baseline in BCVA at Week 8 Baseline and Week 8	ABP 938	6.4 Letters (±8.18 Standard Deviation)
NCT04270747	Macular Degeneration		Aflibercept	6.5 Letters (±8.97 Standard Deviation)
NCT04423718 PULSAR	—	Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48 At baseline and Week 48	Aflibercept 2q8	7.03 scores on a scale (±0.74 Standard Error)
			Aflibercept HDq12	6.06 scores on a scale (±0.77 Standard Error)
			Aflibercept HDq16	5.89 scores on a scale (±0.72 Standard Error)
NCT04429503 PHOTON	Diabetes Mellitus, Type 1	Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48 Baseline, Week 48	Aflibercept 2 mg Every 8 Weeks (2q8)	8.67 Letters (±0.73 Standard Error)
			HD Aflibercept Every 16 Weeks (HDq16)	7.23 Letters (±0.71 Standard Error)
			High-dose (HD) Aflibercept Every 12 Weeks (HDq12)	8.10 Letters (±0.61 Standard Error)
NCT04450329	—	Change From Baseline in Best Corrected Visual Acuity (BCVA) Baseline and Week 8	Eylea (Aflibercept)	6.6 letters (±0.57 Standard Error)
NCT04450329	—		SB15 (Proposed Aflibercept Biosimilar)	6.7 letters (±0.56 Standard Error)
NCT04480463	Macular Degeneration	Change From Baseline in BCVA (Best Corrected Visual Acuity) Baseline to Week 8	Aflibercept	7.7 Letters correctly read
			Aflibercept	5.9 Letters correctly read
			SCD411	5.5 Letters correctly read
			SCD411	9.0 Letters correctly read
NCT04522167 MAGELLAN-AMD	—	Evaluate and Compare Functional Changes in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at Week 8 of Treatment With FYB203 or Eylea Compared to Baseline. Week 8	Eylea® (Aflibercept)	5.6 letters (±0.73 Standard Error)
NCT04522167 MAGELLAN-AMD	—		FYB203 (Proposed Aflibercept Biosimilar)	6.6 letters (±0.73 Standard Error)
NCT04592419 BEACON	Macular Edema	Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in All RVO Patients. Day 1 to Week 24	Aflibercept (Arm B)	15.5 ETDRS Letters (±.81 Standard Error)
NCT04592419 BEACON	Macular Edema		KSI-301 (Arm A)	13.0 ETDRS Letters (±.83 Standard Error)
NCT04592419 BEACON	Macular Edema	Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in BRVO Participants. Day 1 to Week 24	Aflibercept (Arm B)	15.6 ETDRS Letters (±.79 Standard Error)
NCT04592419 BEACON	Macular Edema		KSI-301 (Arm A)	14.2 ETDRS Letters (±.81 Standard Error)
NCT04603937 GLIMMER	Diabetic Retinopathy	Mean Change in BCVA Day 1 to Week 64	Aflibercept (Arm B)	11.5 ETDRS Letters (±0.81 Standard Error)
NCT04603937 GLIMMER	Diabetic Retinopathy	Mean Change in BCVA Day 1 to Week 64	KSI-301 (Arm A)	6.7 ETDRS Letters (±0.80 Standard Error)
NCT04611152 GLEAM	Diabetic Retinopathy	Mean Change in BCVA Day 1 to Week 64	Aflibercept (Arm B)	9.5 ETDRS Letters (±0.85 Standard Error)
NCT04611152 GLEAM	Diabetic Retinopathy	Mean Change in BCVA Day 1 to Week 64	KSI-301 (Arm A)	5.6 ETDRS Letters (±0.83 Standard Error)
NCT04740905 BALATON	Macular Edema	Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 From Baseline through Week 24	Arm A: Faricimab Q4W (Part 1)	16.9 ETDRS Letters
NCT04740905 BALATON	Macular Edema		Arm B: Aflibercept Q4W (Part 1)	17.5 ETDRS Letters
NCT04740931 COMINO	Macular Edema	Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 From Baseline through Week 24	Arm A: Faricimab Q4W (Part 1)	16.9 ETDRS Letters
NCT04740931 COMINO	Macular Edema		Arm B: Aflibercept Q4W (Part 1)	17.3 ETDRS Letters
NCT04757636 COAST	Macular Degeneration	Mean Change in Early Treatment Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letters Baseline to Week 52	2.0 mg Aflibercept With Extended Dosing 2.0 mg OPT-302	12.82 Letters read (±0.728 Standard Error)
			2.0 mg Aflibercept With Sham	13.66 Letters read (±0.728 Standard Error)
			2.0 mg Aflibercept With Standard Dosing 2.0 mg OPT-302	13.48 Letters read (±0.729 Standard Error)
NCT04964089 DAYLIGHT	Macular Degeneration	Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. Day 1 to Week 48	Aflibercept (Treatment Group B)	4.6 ETDRS Letters (±0.76 Standard Error)
NCT04964089 DAYLIGHT	Macular Degeneration		KSI-301 (Treatment Group A)	2.5 ETDRS Letters (±0.78 Standard Error)
NCT05704725	—	Percentage of IVT Injections Successfully Administered Day of IVT injection (study day 1)	ABP 938	100 Percentage of Successful Injections
NCT05704725	—		Aflibercept	100 Percentage of Successful Injections
NCT05850520 QUASAR	—	Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36 At Week 36	Aflibercept 2q4	17.5 Letters (±0.7 Standard Error)
			Aflibercept 8q8/3	17.4 Letters (±0.7 Standard Error)
			Aflibercept 8q8/5	18.3 Letters (±0.6 Standard Error)

Publications by year

1976–2026: 594 publications.

1976

1981

1984

1985

1986

1988

1989

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

Publications by indication

Macular Degeneration (99)

Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto.
Pharmacol Res Perspect · 2026 · PMID 41857488 · NCT04270747
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration.
Expert Opin Biol Ther · 2025 · PMID 40512025 · NCT05155293
Infographic: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE).
Eye (Lond) · 2024 · PMID 38123670 · NCT06683950
Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab.
Ophthalmol Retina · 2024 · PMID 38040055 · NCT06683950
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lancet · 2024 · PMID 38461841 · NCT06683950

Diabetic Retinopathy (77)

Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study.
Ophthalmology · 2026 · PMID 41887289 · NCT04469595
Intravitreal Aflibercept for the Treatment of Diabetic Retinopathy Among Patients Who Completed PANORAMA: 1-Year Outcomes from the VOYAGE Extension Study.
J Pers Med · 2025 · PMID 41295257 · NCT04708145
Expanding insights from the VISTA phase III trial: longitudinal comparative assessment of ellipsoid zone integrity and volumetric fluid dynamics.
Sci Rep · 2025 · PMID 41350590 · NCT01363440
Efficacy of fluocinolone acetonide implant in diabetic macular edema patients previously treated with dexamethasone implant: A systematic review and meta-analysis.
Pak J Med Sci · 2025 · PMID 40980399 · NCT07301775
Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial.
Ophthalmol Retina · 2024 · PMID 37696393 · NCT03531294

Macular Edema (49)

Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials.
Ophthalmol Retina · 2025 · PMID 40107501 · NCT04740931
Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.
Ophthalmology · 2024 · PMID 38280653 · NCT04740931
Update on Retinal Vein Occlusion.
Asia Pac J Ophthalmol (Phila) · 2023 · PMID 36912792 · NCT04740905
Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study.
Int J Retina Vitreous · 2023 · PMID 31016030 · NCT01870427
Predictive value of retinal oximetry, optical coherence tomography angiography and microperimetry in patients with treatment-naïve branch retinal vein occlusion.
Int J Retina Vitreous · 2023 · PMID 37381014 · NCT03651011

Wet Macular Degeneration (26)

Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.
Graefes Arch Clin Exp Ophthalmol · 2026 · PMID 37294433 · NCT03823287
Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration.
JAMA Ophthalmol · 2026 · PMID 41712218 · NCT03823300
Reduction in Pigment Epithelial Detachment Thickness with Faricimab versus Aflibercept 2 mg during Head-to-Head Dosing in TENAYA/LUCERNE.
Ophthalmol Sci · 2026 · PMID 42005909 · NCT03823300
Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): update to study protocol and addition of a statistical analysis plan and health economic analysis plan for a randomised controlled surgical trial.
Trials · 2025 · PMID 40229856 · NCT04663750
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Ophthalmology · 2024 · PMID 38382813 · NCT03823300

Retinal Vein Occlusion (26)

SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Ophthalmology · 2023 · PMID 37220815 · NCT01969708
SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes.
Am J Ophthalmol · 2023 · PMID 36584835 · NCT01969708
Intraocular Pressure in Eyes With Retinal Vein Occlusion Compared With Fellow Eyes: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 27.
JAMA Ophthalmol · 2023 · PMID 37943541 · NCT01969708
Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion.
Am J Ophthalmol · 2022 · PMID 35461831 · NCT01969708
Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial.
JAMA Ophthalmol · 2022 · PMID 31169862 · NCT01969708

Colorectal Neoplasms (26)

Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.
NPJ Precis Oncol · 2026 · PMID 41530374 · NCT00561470
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial.
JAMA Oncol · 2025 · PMID 40531517 · NCT03186326
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
JAMA Oncol · 2025 · PMID 37535388 · NCT03186326
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
Cancers (Basel) · 2024 · PMID 38672597 · NCT02384759
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
Cancer Immunol Immunother · 2024 · PMID 38236249 · NCT02298959

Publications by journal

Ophthalmology81 papers
Retina42 papers
JAMA Ophthalmol36 papers
Br J Ophthalmol35 papers
Am J Ophthalmol26 papers
Ophthalmol Retina14 papers
Arch Ophthalmol14 papers
Graefes Arch Clin Exp Ophthalmol13 papers
N Engl J Med13 papers
Ophthalmol Ther12 papers

Trial-results highlights

In studies investigating aflibercept for macular degeneration, primary outcomes focused on maintaining vision. In NCT00509795 (VIEW1), the percentage of patients who maintained vision at Week 52 was 95.9 percentage for the IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 arm, 95.1 percentage for the IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 arm, and 95.1 percentage for the IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 arm. The Ranibizumab 0.5mg Q4 arm reported 94.4 percentage of patients. Similarly, in NCT00637377 (VIEW 2), the percentage of participants who maintained vision at Week 52 was 96.27 Percentage for the Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 arm, 95.62 Percentage for the Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 arm, and 95.56 Percentage for the Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 arm. The Ranibizumab 0.5mg Q4 arm reported 94.42 Percentage of participants.

For ovarian neoplasms, the primary outcome in NCT00327444 was Time to Repeat Paracentesis (TRP). The aflibercept arm reported 55.1 days, while the placebo arm reported 23.3 days. In colorectal neoplasms, the VELOUR study (NCT00561470) examined Overall Survival (OS). The aflibercept/FOLFIRI arm had an OS of 13.50 months, and the placebo/FOLFIRI arm had an OS of 12.06 months.

Studies in other cancer types also reported Overall Survival (OS) as a primary outcome. In neoplasm metastasis, the VENICE study (NCT00519285) reported an Overall Survival Time of 22.14 months for the aflibercept arm and 21.22 months for the placebo arm. For lung neoplasms, the VITAL study (NCT00532155) reported an OS of 10.05 months for the aflibercept/Docetaxel arm and 10.41 months for the placebo/Docetaxel arm. In pancreatic neoplasms, the VANILLA study (NCT00574275) reported an OS of 6.54 months for the aflibercept and Gemcitabine arm and 7.75 months for the placebo and Gemcitabine arm. All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.

All Aflibercept publications (594)

2026 (15 papers)

Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.
Teo KYC, Yoon YH, Honda S, et al. · Ophthalmol Ther · 2026 · Derived
PubMed: PMID 41903075 · NCT02120950 (PLANET)
Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.
Takahashi K, Cheung CMG, Iida T, et al. · Graefes Arch Clin Exp Ophthalmol · 2026 · Derived
PubMed: PMID 37294433 · NCT03823287 · Wet Macular Degeneration
Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial.
Suzuma K, Murata T, Shimura M, et al. · Jpn J Ophthalmol · 2026 · Derived
PubMed: PMID 41452566 · NCT04429503 (PHOTON) · Diabetes Mellitus, Type 1
Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study.
Singer MA, Wykoff CC, Riemann CD, et al. · Ophthalmology · 2026 · Derived
PubMed: PMID 41887289 · NCT04469595 (NEW DAY) · Diabetic Retinopathy
Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial.
Sheth VS, Schlottmann P, Lai TYY, et al. · Ophthalmology · 2026 · Derived
PubMed: PMID 41534798 · NCT03622580
Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.
Pu T, Peddle AM, Wirapati P, et al. · NPJ Precis Oncol · 2026 · Derived
PubMed: PMID 41530374 · NCT00561470 (VELOUR) · Colorectal Neoplasms
Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration.
Pitcher JD, Koh AHC, Tan CS, et al. · JAMA Ophthalmol · 2026 · Derived
PubMed: PMID 41712218 · NCT03823300 · Wet Macular Degeneration
Reduction in Pigment Epithelial Detachment Thickness with Faricimab versus Aflibercept 2 mg during Head-to-Head Dosing in TENAYA/LUCERNE.
Lim JI, Ambresin A, Avery RL, et al. · Ophthalmol Sci · 2026 · Derived
PubMed: PMID 42005909 · NCT03823300 · Wet Macular Degeneration
Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema: 1-Year Results from the China RHINE Subpopulation.
Li X, Liu X, Jiang Q, et al. · Ophthalmol Ther · 2026 · Derived
PubMed: PMID 41961203 · NCT03622593 (RHINE)
Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.
Lee WK, Wong TY, Chen SJ, et al. · JAMA Ophthalmol · 2026 · Derived
PubMed: PMID 41411005 · NCT04423718 (PULSAR)
Impact of AI-enhanced three-dimensional OCT scans on disease activity assessment in patients with nAMD: the RAZORBILL study.
Kortuem KU, Zarranz-Ventura J, Bandello F, et al. · Br J Ophthalmol · 2026 · Derived
PubMed: PMID 42082322 · NCT04662944 (RAZORBILL)
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial.
Do DV, Wykoff CC, Sivaprasad S, et al. · Ophthalmology · 2026 · Derived
PubMed: PMID 41223900 · NCT04429503 (PHOTON) · Diabetes Mellitus, Type 1
Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto.
Chow V, Zhou M, Mytych DT, et al. · Pharmacol Res Perspect · 2026 · Derived
PubMed: PMID 41857488 · NCT04270747 · Macular Degeneration
Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial.
Chang A, Sun X, Iida T, et al. · Asia Pac J Ophthalmol (Phila) · 2026 · Derived
PubMed: PMID 41519383 · NCT04423718 (PULSAR)
Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration.
Balser S, Capsius B, Hole R, et al. · BMJ Open Ophthalmol · 2026 · Derived
PubMed: PMID 41494750 · NCT04522167 (MAGELLAN-AMD)

2025 (16 papers)

Intravitreal Aflibercept for the Treatment of Diabetic Retinopathy Among Patients Who Completed PANORAMA: 1-Year Outcomes from the VOYAGE Extension Study.
Zhou AW, Teagle GM, Baumann LM, et al. · J Pers Med · 2025 · Derived
PubMed: PMID 41295257 · NCT04708145 (VOYAGE) · Diabetic Retinopathy
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial.
Taïeb J, Sullo FG, Lecanu A, et al. · JAMA Oncol · 2025 · Derived
PubMed: PMID 40531517 · NCT03186326 (SAMCO) · Colorectal Neoplasms
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
Taïeb J, Bouche O, André T, et al. · JAMA Oncol · 2025 · Derived
PubMed: PMID 37535388 · NCT03186326 (SAMCO) · Colorectal Neoplasms
Expanding insights from the VISTA phase III trial: longitudinal comparative assessment of ellipsoid zone integrity and volumetric fluid dynamics.
Matar K, Indurkar A, Yordi S, et al. · Sci Rep · 2025 · Derived
PubMed: PMID 41350590 · NCT01363440 (VISTA DME) · Diabetic Retinopathy
Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): update to study protocol and addition of a statistical analysis plan and health economic analysis plan for a randomised controlled surgical trial.
Lee CN, Desai R, Ramazzotto L, et al. · Trials · 2025 · Derived
PubMed: PMID 40229856 · NCT04663750 (TIGER) · Wet Macular Degeneration
Interventions for central serous chorioretinopathy: a network meta-analysis.
Lange CA, Qureshi R, Pauleikhoff L, et al. · Cochrane Database Syst Rev · 2025 · Derived
PubMed: PMID 40522203 · NCT01971190 · Central Serous Chorioretinopathy
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.
Korobelnik JF, Lanzetta P, Leal S, et al. · Ophthalmology · 2025 · Derived
PubMed: PMID 40876598 · NCT04423718 (PULSAR)
Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER.
Khanani AM, Sadda SR, Sarraf D, et al. · Ophthalmol Retina · 2025 · Derived
PubMed: PMID 39033924 · NCT02434328 (HARRIER) · Choroidal Neovascularization
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS.
Jaffe GJ, Deák G, Gibson K, et al. · Retina · 2025 · Derived
PubMed: PMID 40668667 · NCT03622580
Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE.
Goldberg RA, Mar FA, Csaky K, et al. · Ophthalmol Retina · 2025 · Derived
PubMed: PMID 39580145 · NCT03622593 (RHINE)
Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials.
Danzig CJ, Dinah C, Ghanchi F, et al. · Ophthalmol Retina · 2025 · Derived
PubMed: PMID 40107501 · NCT04740931 (COMINO) · Macular Edema
Aflibercept With vs Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
Chong YJ, Teo KYC, Wong W, et al. · JAMA Ophthalmol · 2025 · Derived
PubMed: PMID 40146166 · NCT03941587 · Polypoidal Choroidal Vasculopathy
Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials.
Chakravarthy U, Chaudhary V, Sadda SR, et al. · Ophthalmol Sci · 2025 · Derived
PubMed: PMID 40496217 · NCT03622593 (RHINE)
2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohort.
Bailey C, Chandran M, Gale R, et al. · Eye (Lond) · 2025 · Derived
PubMed: PMID 39719502 · NCT03939767 (XTEND)
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration.
Agostini H, Baumane K, Balčiūnienė VJ, et al. · Expert Opin Biol Ther · 2025 · Derived
PubMed: PMID 40512025 · NCT05155293 (ALVOEYE) · Macular Degeneration
Efficacy of fluocinolone acetonide implant in diabetic macular edema patients previously treated with dexamethasone implant: A systematic review and meta-analysis.
Hu W, Ni L, Ying H, et al. · Pak J Med Sci · 2025 · Background
PubMed: PMID 40980399 · NCT07301775 · Diabetic Retinopathy

2024 (33 papers)

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, et al. · Ophthalmology · 2024 · Trial result
PubMed: PMID 38158159 · NCT03622580
Infographic: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE).
Wijesingha N, Sivaprasad S · Eye (Lond) · 2024 · Trial result
PubMed: PMID 38123670 · NCT06683950 · Macular Degeneration
Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab.
Raimondi R, Felfeli T, Bogdanova-Bennet A, et al. · Ophthalmol Retina · 2024 · Trial result
PubMed: PMID 38040055 · NCT06683950 · Macular Degeneration
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
Legoux JL, Faroux R, Barrière N, et al. · Cancers (Basel) · 2024 · Trial result
PubMed: PMID 38672597 · NCT02384759 (FOLFA) · Colorectal Neoplasms
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lanzetta P, Korobelnik JF, Heier JS, et al. · Lancet · 2024 · Trial result
PubMed: PMID 38461841 · NCT06683950 · Macular Degeneration
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, et al. · Ophthalmology · 2024 · Trial result
PubMed: PMID 38382813 · NCT03823300 · Wet Macular Degeneration
Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials.
Zarbin M, Tabano D, Ahmed A, et al. · Ophthalmology · 2024 · Derived
PubMed: PMID 38852921 · NCT03622593 (RHINE)
Bacillary Layer Detachment in Neovascular Age-Related Macular Degeneration from a Phase III Clinical Trial.
Yordi S, Cakir Y, Cetin H, et al. · Ophthalmol Retina · 2024 · Derived
PubMed: PMID 38360182 · NCT02307682 (HAWK) · Choroidal Neovascularization
Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.
Tadayoni R, Paris LP, Danzig CJ, et al. · Ophthalmology · 2024 · Derived
PubMed: PMID 38280653 · NCT04740931 (COMINO) · Macular Edema
Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next.
Stahl A, Nakanishi H, Lepore D, et al. · JAMA Netw Open · 2024 · Derived
PubMed: PMID 38687481 · NCT04015180 (FIREFLEYE next) · Retinopathy of Prematurity
Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.
Stahl A, Azuma N, Wu WC, et al. · Eye (Lond) · 2024 · Derived
PubMed: PMID 38200320 · NCT04004208 (FIREFLEYE) · Retinopathy of Prematurity
Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial.
Patel PJ, Jayaram H, Eleftheriadou M, et al. · Ophthalmol Ther · 2024 · Derived
PubMed: PMID 32557168 · NCT02441816 (VITAL) · Macular Degeneration
Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial.
Li B, Fan K, Zhang T, et al. · Ophthalmol Ther · 2024 · Derived
PubMed: PMID 37987893 · NCT05345236
Impact of Prolonged Persisting Subretinal Fluid on the Outcome of Aflibercept Treatment in Neovascular Age-Related Macular Degeneration.
Lee JH, Kim JH · J Ocul Pharmacol Ther · 2024 · Derived
PubMed: PMID 38489060 · NCT05662943 · Macular Degeneration
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration.
Korobelnik JF, Chaudhary V, Mitchell P, et al. · Ophthalmol Ther · 2024 · Derived
PubMed: PMID 38198053 · NCT03939767 (XTEND)
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.
Kodjikian L, Arias Barquet L, Papp A, et al. · Adv Ther · 2024 · Derived
PubMed: PMID 38183525 · NCT02540954 · Macular Degeneration
Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial.
Kalra G, Wykoff C, Martin A, et al. · Ophthalmol Retina · 2024 · Derived
PubMed: PMID 37696393 · NCT03531294 · Diabetic Retinopathy
Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study.
Giocanti-Aurégan A, Donati S, Hoerauf H, et al. · Ophthalmol Ther · 2024 · Derived
PubMed: PMID 37924481 · NCT03161912 (AURIGA) · Diabetic Retinopathy
Telehealth Diabetes Prevention Program for Adults With Prediabetes in an Academic Medical Center Setting: Protocol for a Hybrid Type III Trial.
Gamble A, Khan T, Hughes A, et al. · JMIR Res Protoc · 2024 · Derived
PubMed: PMID 37955955 · NCT03622580
Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study.
Donati S, Yang CH, Xu X, et al. · Ophthalmol Ther · 2024 · Derived
PubMed: PMID 37924483 · NCT03161912 (AURIGA) · Diabetic Retinopathy
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, et al. · Lancet · 2024 · Derived
PubMed: PMID 38461843 · NCT04429503 (PHOTON) · Diabetes Mellitus, Type 1
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
Baginska J, Nau A, Gomez Diaz I, et al. · Cancer Immunol Immunother · 2024 · Derived
PubMed: PMID 38236249 · NCT02298959 · Colorectal Neoplasms
Management after cataract surgery for patients with diabetic retinopathy: a systematic review and meta-analysis.
Wu J, Zhou Y, Zhen F, et al. · Int Ophthalmol · 2024 · Background
PubMed: PMID 38557801 · NCT07301775 · Diabetic Retinopathy
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort.
Tougeron D, Bibeau F, Chibaudel B, et al. · Eur J Cancer · 2024 · Background
PubMed: PMID 39486163 · NCT05178745 · Colorectal Neoplasms
Progression of diabetic retinopathy following uncomplicated phacoemulsification: A prospective study from South India.
Sruthi R, Saikumar SJ, Gopalakrishnan M, et al. · Oman J Ophthalmol · 2024 · Background
PubMed: PMID 38524349 · NCT07301775 · Diabetic Retinopathy
Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy.
Shye M, Hanna RM, Patel SS, et al. · Clin Kidney J · 2024 · Background
PubMed: PMID 33391740 · NCT06929507 · Diabetes Mellitus
Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes.
Mun Y, Park KH, Park SJ, et al. · PLoS One · 2024 · Background
PubMed: PMID 34111133 · NCT06662994 · Diabetic Retinopathy
Evaluation of a self-imaging OCT for remote diagnosis and monitoring of retinal diseases.
Liu Z, Huang W, Wang Z, et al. · Br J Ophthalmol · 2024 · Background
PubMed: PMID 37903558 · NCT06610747 (DME HOME) · Diabetic Retinopathy
Impact of Angiopoietin-2 on Kidney Diseases.
Li M, Popovic Z, Chu C, et al. · Kidney Dis (Basel) · 2024 · Background
PubMed: PMID 38306230 · NCT06929507 · Diabetes Mellitus
Incidence and Progression of Diabetic Retinopathy After Cataract Surgery: A Systematic Review and Meta-Analysis.
Lee SH, Tseng BY, Wu MC, et al. · Am J Ophthalmol · 2024 · Background
PubMed: PMID 39179126 · NCT07301775 · Diabetic Retinopathy
Diabetic Retinopathy Leading to Blindness- A Review.
Kaur A, Kumar R, Sharma A, et al. · Curr Diabetes Rev · 2024 · Background
PubMed: PMID 38275038 · NCT07301775 · Diabetic Retinopathy
NSAIDs and Corticosteroids for the Postoperative Management of Age-Related Cataract Surgery: A Systematic Review and Meta-analysis.
Haddad JE, Sabbakh NA, Macaron MM, et al. · Am J Ophthalmol · 2024 · Background
PubMed: PMID 37797866 · NCT07301775 · Diabetic Retinopathy
Long-Term Change in Renal Function After Intravitreal Anti-VEGF Treatment for Diabetic Macular Edema: A 2-Year Retrospective Cohort Study.
Fang YC, Lai IP, Lai TT, et al. · Ophthalmol Ther · 2024 · Background
PubMed: PMID 37589931 · NCT06929507 · Diabetes Mellitus

2023 (32 papers)

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Wykoff CC, Brown DM, Reed K, et al. · JAMA Ophthalmol · 2023 · Trial result
PubMed: PMID 37535382 · NCT06683950 · Macular Degeneration
Efficacy and safety of Aflibercept for the treatment of inflammatory choroidal neovascularization: The ALINEA study.
Kodjikian L, Abukhashabah A, Fardeau C, et al. · Acta Ophthalmol · 2023 · Trial result
PubMed: PMID 35822428 · NCT02556229 (ALINEA)
Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration.
Cohen SY, Dominguez M, Coscas F, et al. · Graefes Arch Clin Exp Ophthalmol · 2023 · Trial result
PubMed: PMID 36399178 · NCT02279537 (RAINBOW) · Wet Macular Degeneration
Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis.
Chaudhary V, Holz FG, Wolf S, et al. · Ophthalmol Ther · 2023 · Trial result
PubMed: PMID 35303285 · NCT02581891 (ARIES) · Macular Degeneration
Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.
Woo SJ, Bradvica M, Vajas A, et al. · JAMA Ophthalmol · 2023 · Derived
PubMed: PMID 37289448 · NCT04450329
Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study.
Weber M, Velasque L, Coscas F, et al. · BMJ Open Ophthalmol · 2023 · Derived
PubMed: PMID 31179386 · NCT02279537 (RAINBOW) · Wet Macular Degeneration
Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment: A Meta-Analysis.
Talcott KE, Valentim CCS, Hill L, et al. · Ophthalmol Retina · 2023 · Derived
PubMed: PMID 36774994 · NCT01627249 (Protocol T)
Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema.
Stockwell AD, Chang MC, Mahajan A, et al. · PLoS Genet · 2023 · Derived
PubMed: PMID 37585454 · NCT03622580
Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes.
Sivaprasad S, Ghanchi F, Kelly SP, et al. · Eye (Lond) · 2023 · Derived
PubMed: PMID 36941402 · NCT02850263 (DRAKO) · Diabetic Retinopathy
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.
Singh RP, Barakat MR, Ip MS, et al. · JAMA Ophthalmol · 2023 · Derived
PubMed: PMID 37971723 · NCT03917472 (KINGFISHER) · Diabetic Retinopathy
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, et al. · Jpn J Ophthalmol · 2023 · Derived
PubMed: PMID 36897413 · NCT03622593 (RHINE)
SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Scott IU, Oden NL, VanVeldhuisen PC, et al. · Ophthalmology · 2023 · Derived
PubMed: PMID 37220815 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes.
Scott IU, Oden NL, VanVeldhuisen PC, et al. · Am J Ophthalmol · 2023 · Derived
PubMed: PMID 36584835 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
SUSTAINED BIWEEKLY AFLIBERCEPT FOR REFRACTORY NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The Prospective TRISTAR Study.
Schneider EW, Thomas MK, Recchia FM, et al. · Retina · 2023 · Derived
PubMed: PMID 36728874 · NCT03468296 (TRISTAR) · Macular Degeneration
Update on Retinal Vein Occlusion.
Romano F, Lamanna F, Gabrielle PH, et al. · Asia Pac J Ophthalmol (Phila) · 2023 · Derived
PubMed: PMID 36912792 · NCT04740905 (BALATON) · Macular Edema
Anti-vascular endothelial growth factor for neovascular glaucoma.
Rittiphairoj T, Roberti G, Michelessi M, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 37010901 · NCT02396316 (VEGA) · Glaucoma, Neovascular
Long-term surveillance provides real-world evidences of safety and effectiveness in intravitreal aflibercept treatment for age-related macular degeneration.
Ozawa Y, Ohgami K, Sasaki K, et al. · Sci Rep · 2023 · Derived
PubMed: PMID 37391547 · NCT01756248 · Macular Degeneration
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK, Glassman AR, Josic K, et al. · JAMA · 2023 · Derived
PubMed: PMID 36749332 · NCT02634333 · Diabetic Retinopathy
Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
Lukacs R, Schneider M, Nagy ZZ, et al. · BMC Ophthalmol · 2023 · Derived
PubMed: PMID 36932356 · NCT00637377 (VIEW 2) · Macular Degeneration
Use of Correct and Incorrect Methods of Accounting for Age in Studies of Epigenetic Accelerated Aging: Implications and Recommendations for Best Practices.
Krieger N, Chen JT, Testa C, et al. · Am J Epidemiol · 2023 · Derived
PubMed: PMID 36721372 · NCT02581891 (ARIES) · Macular Degeneration
Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study.
Khurana RN, Chang LK, Bansal AS, et al. · Int J Retina Vitreous · 2023 · Derived
PubMed: PMID 31016030 · NCT01870427 (NEWTON) · Macular Edema
A Novel Bispecific Fusion Protein Targeting C3b/C4b and VEGF in Patients With nAMD: A Randomized, Open-Label, Phase 1b Study.
Jia H, Li T, Sun J, et al. · Am J Ophthalmol · 2023 · Derived
PubMed: PMID 36410472 · NCT04370379
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K, Rogozińska E, Platt S, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 37185961 · NCT00327171 · Neoplasms
Predictive value of retinal oximetry, optical coherence tomography angiography and microperimetry in patients with treatment-naïve branch retinal vein occlusion.
Frederiksen KH, Pedersen FN, Vergmann AS, et al. · Int J Retina Vitreous · 2023 · Derived
PubMed: PMID 37381014 · NCT03651011 (NIRVANA) · Macular Edema
INCIDENCE OF NEW DIABETIC MACULAR EDEMA IN FELLOW EYES OF PATIENTS IN THE VISTA AND VIVID STUDIES.
Dhoot DS, Moini H, Reed K, et al. · Retina · 2023 · Derived
PubMed: PMID 36265076 · NCT01363440 (VISTA DME) · Diabetic Retinopathy
Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
Dhoot DS, Moini H, Reed K, et al. · Eye (Lond) · 2023 · Derived
PubMed: PMID 35440699 · NCT01363440 (VISTA DME) · Diabetic Retinopathy
Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.
Dervenis P, Dervenis N, Smith JM, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 37260074 · NCT01805297 · Vitreous Hemorrhage
Changes in activity impairment and work productivity after treatment for vitreous hemorrhage due to proliferative diabetic retinopathy: Secondary outcomes from a randomized controlled trial (DRCR Retina Network Protocol AB).
Beaulieu WT, Maguire MG, Antoszyk AN, et al. · PLoS One · 2023 · Derived
PubMed: PMID 37972038 · NCT02858076 (AB) · Vitreous Hemorrhage
Intraocular Pressure in Eyes With Retinal Vein Occlusion Compared With Fellow Eyes: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 27.
Aref AA, Scott IU, Oden NL, et al. · JAMA Ophthalmol · 2023 · Derived
PubMed: PMID 37943541 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Glycemic control and macular edema in patients undergoing cataract surgery.
Rachmilevich A, Yanculovich N, Hazan I, et al. · Prim Care Diabetes · 2023 · Background
PubMed: PMID 36599797 · NCT07301775 · Diabetic Retinopathy
Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation.
Kropp M, Golubnitschaja O, Mazurakova A, et al. · EPMA J · 2023 · Background
PubMed: PMID 36866156 · NCT07301775 · Diabetic Retinopathy
Real-world visual outcomes of cataract surgery based on population-based studies: a systematic review.
Han X, Zhang J, Liu Z, et al. · Br J Ophthalmol · 2023 · Background
PubMed: PMID 35410876 · NCT07301775 · Diabetic Retinopathy

2022 (60 papers)

Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis.
Wolf S, Holz FG, Midena E, et al. · Ophthalmol Ther · 2022 · Trial result
PubMed: PMID 35821380 · NCT02581891 (ARIES) · Macular Degeneration
Hypothetical Switch of Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis.
Tuerksever C, Somfai GM, Oesch S, et al. · Ophthalmol Ther · 2022 · Trial result
PubMed: PMID 35066801 · NCT02581891 (ARIES) · Macular Degeneration
Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes.
Sivaprasad S, Ghanchi F, Kelly SP, et al. · Eye (Lond) · 2022 · Trial result
PubMed: PMID 34244670 · NCT02850263 (DRAKO) · Diabetic Retinopathy
Real-World Data on Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 24-Month Outcomes.
Shimura M, Fukumatsu M, Tsujimura J, et al. · Clin Ophthalmol · 2022 · Trial result
PubMed: PMID 35256840 · NCT01783925 · Macular Degeneration
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
Okada AA, Takahashi K, Ohji M, et al. · Adv Ther · 2022 · Trial result
PubMed: PMID 35503499 · NCT02305238 (ALTAIR) · Macular Degeneration
PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration.
Nicolò M, Ciucci F, Nardi M, et al. · Graefes Arch Clin Exp Ophthalmol · 2022 · Trial result
PubMed: PMID 35511286 · NCT02289924 (PERSEUS-IT) · Wet Macular Degeneration
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.
Mitchell P, Holz FG, Hykin P, et al. · Retina · 2022 · Trial result
PubMed: PMID 33782365 · NCT05662943 · Macular Degeneration
Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema.
Korobelnik JF, Daien V, Faure C, et al. · Sci Rep · 2022 · Trial result
PubMed: PMID 36309572 · NCT02924311 (APOLLON) · Diabetic Retinopathy
EFFICACY AND SAFETY OF AFLIBERCEPT FOR THE TREATMENT OF IDIOPATHIC CHOROIDAL NEOVASCULARIZATION IN YOUNG PATIENTS: The INTUITION Study.
Kodjikian L, Tadayoni R, Souied EH, et al. · Retina · 2022 · Trial result
PubMed: PMID 34620799 · NCT02257502 (INTUITION)
Difference Between the Incidence of Retinal Fluid Subtypes and Their Association with Visual Outcomes According to the Types of Macular Neovascularization in a Korean Population.
Kim JH, Kim JW, Kim CG, et al. · J Ocul Pharmacol Ther · 2022 · Trial result
PubMed: PMID 35119292 · NCT05662943 · Macular Degeneration
Prechoroidal Cleft in Type 3 Neovascularization: Incidence, Timing, and Its Association with Visual Outcome.
Kim JH, Chang YS, Kim JW, et al. · J Ophthalmol · 2022 · Trial result
PubMed: PMID 30581602 · NCT04655482
Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept.
de Oliveira Dias JR, de Andrade GC, Novais EA, et al. · Int J Retina Vitreous · 2022 · Trial result
PubMed: PMID 27847621 · NCT03313401 · Macular Degeneration
Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan.
Cheng CK, Chen SJ, Chen JT, et al. · BMC Ophthalmol · 2022 · Trial result
PubMed: PMID 35033037 · NCT05662943 · Macular Degeneration
IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review.
Chaudhary V, Matonti F, Zarranz-Ventura J, et al. · Retina · 2022 · Trial result
PubMed: PMID 34393212 · NCT05662943 · Macular Degeneration
Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data.
Ziemssen F, Schlottman PG, Lim JI, et al. · Int J Retina Vitreous · 2022 · Derived
PubMed: PMID 27847634 · NCT01363440 (VISTA DME) · Diabetic Retinopathy
Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials.
Wykoff CC, Marcus DM, Midena E, et al. · JAMA Ophthalmol · 2022 · Derived
PubMed: PMID 28006063 · NCT01363440 (VISTA DME) · Diabetic Retinopathy
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, et al. · Lancet · 2022 · Derived
PubMed: PMID 35085503 · NCT03622593 (RHINE)
Intravitreal aflibercept for the treatment of patients with neovascular age-related macular degeneration in routine clinical practice in Latin America: the AQUILA study.
Wu L, Bordon AF, Charles M, et al. · Int J Retina Vitreous · 2022 · Derived
PubMed: PMID 36258240 · NCT03470103 (AQUILA) · Macular Degeneration
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study.
Weber M, Kodjikian L, Coscas F, et al. · BMJ Open Ophthalmol · 2022 · Derived
PubMed: PMID 32518833 · NCT02279537 (RAINBOW) · Wet Macular Degeneration
Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy.
Teo KYC, Jordan-Yu JM, Tan ACS, et al. · Br J Ophthalmol · 2022 · Derived
PubMed: PMID 33574033 · NCT03117634 · Macular Degeneration
Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies.
Sunakawa Y, Takahashi K, Kawaguchi O, et al. · Invest New Drugs · 2022 · Derived
PubMed: PMID 35771301 · NCT00545246 · Neoplasms
Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes.
Sugimoto M, Handa C, Hirano K, et al. · Graefes Arch Clin Exp Ophthalmol · 2022 · Derived
PubMed: PMID 35652946 · NCT02425501 · Macular Edema
Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
Stahl A, Sukgen EA, Wu WC, et al. · JAMA · 2022 · Derived
PubMed: PMID 35881122 · NCT04004208 (FIREFLEYE) · Retinopathy of Prematurity
Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
Singh RP, Jhaveri C, Wykoff CC, et al. · Ophthalmol Retina · 2022 · Derived
PubMed: PMID 34968756 · NCT02307682 (HAWK) · Choroidal Neovascularization
Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial.
Silva R, Arias L, Nunes S, et al. · Ophthalmologica · 2022 · Derived
PubMed: PMID 34348351 · NCT02495181 (ATLANTIC) · Polypoidal Choroidal Vasculopathy
One-year outcomes of the treat-and-extend regimen using aflibercept for the treatment of diabetic macular edema.
Sheu SJ, Yang CH, Lai CC, et al. · J Chin Med Assoc · 2022 · Derived
PubMed: PMID 34974510 · NCT04288232
Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion.
Scott IU, VanVeldhuisen PC, Oden NL, et al. · Am J Ophthalmol · 2022 · Derived
PubMed: PMID 35461831 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial.
Scott IU, VanVeldhuisen PC, Barton F, et al. · JAMA Ophthalmol · 2022 · Derived
PubMed: PMID 31169862 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Intravitreal aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin America: the AQUILA study.
Rodríguez FJ, Wu L, Bordon AF, et al. · Int J Retina Vitreous · 2022 · Derived
PubMed: PMID 35918743 · NCT03470103 (AQUILA) · Macular Degeneration
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
Rahma OE, Tyan K, Giobbie-Hurder A, et al. · J Immunother Cancer · 2022 · Derived
PubMed: PMID 35264434 · NCT02298959 · Colorectal Neoplasms
Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment.
Pongsachareonnont P, Mak MYK, Hurst CP, et al. · Clin Ophthalmol · 2022 · Derived
PubMed: PMID 30310267 · NCT02218177 · Macular Degeneration
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis.
Pessoa B, Malheiro L, Carneiro I, et al. · Clin Ophthalmol · 2022 · Derived
PubMed: PMID 33519187 · NCT04018833 (SWITCH) · Diabetic Retinopathy
A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors.
Perez K, Kulke MH, Horick NK, et al. · Pancreas · 2022 · Derived
PubMed: PMID 36395401 · NCT01782443 · Neoplasm Metastasis
SYSTEMATIC CORRELATION OF CENTRAL SUBFIELD THICKNESS WITH RETINAL FLUID VOLUMES QUANTIFIED BY DEEP LEARNING IN THE MAJOR EXUDATIVE MACULAR DISEASES.
Pawloff M, Bogunovic H, Gruber A, et al. · Retina · 2022 · Derived
PubMed: PMID 34934034 · NCT01627249 (Protocol T)
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol.
Ottaiano A, Scala S, Santorsola M, et al. · Ther Adv Med Oncol · 2022 · Derived
PubMed: PMID 33854566 · NCT04397601 (ARBITRATION) · Colorectal Neoplasms
Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection.
Nawar AE, Wasfy T, Shafik HM, et al. · BMC Ophthalmol · 2022 · Derived
PubMed: PMID 35768859 · NCT04290195
Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies.
Midena E, Gillies M, Katz TA, et al. · J Ophthalmol · 2022 · Derived
PubMed: PMID 29785301 · NCT01363440 (VISTA DME) · Diabetic Retinopathy
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
Maturi RK, Glassman AR, Josic K, et al. · JAMA Ophthalmol · 2022 · Derived
PubMed: PMID 33784735 · NCT02634333 · Diabetic Retinopathy
Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage.
Mansour AM, Ashraf M, El Jawhari KM, et al. · Int J Retina Vitreous · 2022 · Derived
PubMed: PMID 31956432 · NCT02486484 (Zaltrap) · Macular Degeneration
TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
Khanani AM, Guymer RH, Basu K, et al. · Ophthalmol Sci · 2022 · Derived
PubMed: PMID 36246941 · NCT03823300 · Wet Macular Degeneration
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Jhaveri CD, Glassman AR, Ferris FL, et al. · N Engl J Med · 2022 · Derived
PubMed: PMID 35833805 · NCT03321513 (DRCR AC)
Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.
Jackson TL, Bunce C, Desai R, et al. · Trials · 2022 · Derived
PubMed: PMID 35101110 · NCT04663750 (TIGER) · Wet Macular Degeneration
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, et al. · Lancet · 2022 · Derived
PubMed: PMID 35085502 · NCT03823287 · Wet Macular Degeneration
Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial.
Heier JS, Brown DM, Shah SP, et al. · JAMA Ophthalmol · 2022 · Derived
PubMed: PMID 33734306 · NCT02462889 (PRO-CON) · Macular Degeneration
Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR, Beaulieu WT, Maguire MG, et al. · JAMA Ophthalmol · 2022 · Derived
PubMed: PMID 33956075 · NCT02858076 (AB) · Vitreous Hemorrhage
Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial.
Garweg JG, Štefanickova J, Hoyng C, et al. · Adv Ther · 2022 · Derived
PubMed: PMID 35412227 · NCT02818998 (VIOLET) · Macular Edema
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.
Fernández-Martos C, Pericay C, Losa F, et al. · JAMA Oncol · 2022 · Derived
PubMed: PMID 31465088 · NCT02340949 (RIA) · Rectal Neoplasms
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.
Eter N, Singh RP, Abreu F, et al. · Ophthalmol Sci · 2022 · Derived
PubMed: PMID 36246184 · NCT03622593 (RHINE)
Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study.
Chen YX, Li XX, Yoon YH, et al. · Clin Ophthalmol · 2022 · Derived
PubMed: PMID 32210527 · NCT01783886 (VIVID EAST) · Macular Edema
Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
Brown DM, Wykoff CC, Boyer D, et al. · JAMA Ophthalmol · 2022 · Derived
PubMed: PMID 34351414 · NCT02718326 (PANORAMA)
Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis.
Babiuch AS, Conti TF, Conti FF, et al. · Int J Retina Vitreous · 2022 · Derived
PubMed: PMID 31367468 · NCT02559180 (SwapTwo) · Diabetic Retinopathy
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, et al. · JAMA Ophthalmol · 2022 · Derived
PubMed: PMID 34709363 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Outcomes of Patients With Active Diabetic Macular Edema at the Time of Cataract Surgery Managed With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Starr MR, Mahr MA, Smith WM, et al. · Am J Ophthalmol · 2022 · Background
PubMed: PMID 33852907 · NCT07301775 · Diabetic Retinopathy
Early DMO: a predictor of poor outcomes following cataract surgery in diabetic patients. The DICAT-II study.
Panozzo G, Mura GD, Franzolin E, et al. · Eye (Lond) · 2022 · Background
PubMed: PMID 34345028 · NCT05080803
Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial.
Maguire MG, Liu D, Bressler SB, et al. · JAMA Ophthalmol · 2022 · Background
PubMed: PMID 34673898 · NCT06610747 (DME HOME) · Diabetic Retinopathy
Evaluation of a self-imaging SD-OCT system designed for remote home monitoring.
Kim JE, Tomkins-Netzer O, Elman MJ, et al. · BMC Ophthalmol · 2022 · Background
PubMed: PMID 35689210 · NCT06610747 (DME HOME) · Diabetic Retinopathy
Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15.
Etheridge T, Blodi B, Oden N, et al. · Ophthalmol Retina · 2022 · Background
PubMed: PMID 33373715 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.
Bulirsch LM, Saßmannshausen M, Nadal J, et al. · Br J Ophthalmol · 2022 · Background
PubMed: PMID 33846161 · NCT05710471 · Macular Degeneration
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial.
Bressler NM, Odia I, Maguire M, et al. · JAMA Ophthalmol · 2022 · Background
PubMed: PMID 31246237 · NCT01627249 (Protocol T)
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept.
Adrean SD, Knight D, Chaili S, et al. · Int J Retina Vitreous · 2022 · Background
PubMed: PMID 35144686 · NCT06662994 · Diabetic Retinopathy

2021 (39 papers)

Notion of tolerating subretinal fluid in neovascular AMD: understanding the fine print before the injection pause.
Sharma A, Parachuri N, Kumar N, et al. · Br J Ophthalmol · 2021 · Trial result
PubMed: PMID 32980815 · NCT05662943 · Macular Degeneration
Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy.
Schworm B, Luft N, Keidel LF, et al. · BMC Ophthalmol · 2021 · Trial result
PubMed: PMID 34193089 · NCT05662410
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration.
Pellegrini M, Bernabei F, Mercanti A, et al. · Graefes Arch Clin Exp Ophthalmol · 2021 · Trial result
PubMed: PMID 33048236 · NCT05662410
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Lapeyre-Prost A, Pernot S, Sigrand J, et al. · Clin Colorectal Cancer · 2021 · Trial result
PubMed: PMID 32921581 · NCT02181556 · Colorectal Neoplasms
Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society.
Chaikitmongkol V, Sagong M, Lai TYY, et al. · Asia Pac J Ophthalmol (Phila) · 2021 · Trial result
PubMed: PMID 34839342 · NCT05662943 · Macular Degeneration
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW.
Weber M, Dominguez M, Coscas F, et al. · BMC Ophthalmol · 2021 · Derived
PubMed: PMID 32450838 · NCT02279537 (RAINBOW) · Wet Macular Degeneration
Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy.
Vyas CH, Cheung CMG, Tan C, et al. · BMJ Open · 2021 · Derived
PubMed: PMID 34266844 · NCT03941587 · Polypoidal Choroidal Vasculopathy
Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa.
Strong SA, Peto T, Bunce C, et al. · Br J Ophthalmol · 2021 · Derived
PubMed: PMID 32041720 · NCT02661711 (AMOUR) · Macular Edema
European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer.
Stanel SC, Sjöberg J, Salmonson T, et al. · ESMO Open · 2021 · Derived
PubMed: PMID 28761750 · NCT00561470 (VELOUR) · Colorectal Neoplasms
Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
Scott IU, Oden NL, VanVeldhuisen PC, et al. · JAMA Ophthalmol · 2021 · Derived
PubMed: PMID 31600368 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.
Roberts PK, Vogl WD, Gerendas BS, et al. · JAMA Ophthalmol · 2021 · Derived
PubMed: PMID 32722799 · NCT01627249 (Protocol T)
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
Razavi S, Kodjikian L, Giocanti-Aurégan A, et al. · BMC Ophthalmol · 2021 · Derived
PubMed: PMID 33596867 · NCT02321241 (TITAN) · Wet Macular Degeneration
Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
Ohji M, Okada AA, Sasaki K, et al. · Graefes Arch Clin Exp Ophthalmol · 2021 · Derived
PubMed: PMID 34283294 · NCT02305238 (ALTAIR) · Macular Degeneration
Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients.
Nawar AE, Shafik HM · BMC Ophthalmol · 2021 · Derived
PubMed: PMID 33076864 · NCT04290195
GENETICS OF LARGE PIGMENT EPITHELIAL DETACHMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Mouallem-Beziere A, Blanco-Garavito R, Richard F, et al. · Retina · 2021 · Derived
PubMed: PMID 30681643 · NCT02157077 (ARI2) · Macular Degeneration
Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies.
Moshfeghi DM, Thompson D, Saroj N, et al. · Br J Ophthalmol · 2021 · Derived
PubMed: PMID 31826853 · NCT00637377 (VIEW 2) · Macular Degeneration
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J, Srivastava SK, Jaffe GJ, et al. · Ophthalmology · 2021 · Derived
PubMed: PMID 33207259 · NCT02307682 (HAWK) · Choroidal Neovascularization
Cost-effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China.
Ming J, Zhang Y, Xu X, et al. · J Comp Eff Res · 2021 · Derived
PubMed: PMID 31904267 · NCT01783886 (VIVID EAST) · Macular Edema
Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging.
Lu L, Dercle L, Zhao B, et al. · Nat Commun · 2021 · Derived
PubMed: PMID 34789774 · NCT00561470 (VELOUR) · Colorectal Neoplasms
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study.
Korobelnik JF, Larsen M, Eter N, et al. · Am J Ophthalmol · 2021 · Derived
PubMed: PMID 33556381 · NCT02800642 (CENTERA) · Retinal Vein Occlusion
Efficacy of intravitreal AFlibercept injection For Improvement of retinal Nonperfusion In diabeTic retinopathY (AFFINITY study).
Kim YJ, Yeo JH, Son G, et al. · BMJ Open Diabetes Res Care · 2021 · Derived
PubMed: PMID 33077475 · NCT03006081 · Diabetic Retinopathy
Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.
Khurana RN, Oden NL, VanVeldhuisen PC, et al. · Graefes Arch Clin Exp Ophthalmol · 2021 · Derived
PubMed: PMID 33415354 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study.
Inatani M, Higashide T, Matsushita K, et al. · Adv Ther · 2021 · Derived
PubMed: PMID 33330959 · NCT03639675 (VENERA) · Glaucoma, Neovascular
Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial.
Inatani M, Higashide T, Matsushita K, et al. · Adv Ther · 2021 · Derived
PubMed: PMID 33330958 · NCT02396316 (VEGA) · Glaucoma, Neovascular
Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study.
Figueiredo N, Srivastava SK, Singh RP, et al. · Ophthalmol Retina · 2021 · Derived
PubMed: PMID 31757691 · NCT02503540 (PERMEATE) · Macular Edema
Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
Clemens CR, Alten F, Termühlen J, et al. · Graefes Arch Clin Exp Ophthalmol · 2021 · Derived
PubMed: PMID 32306096 · NCT03370380 · Retinal Detachment
MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.
Camera S, Deleporte A, Bregni G, et al. · Clin Colorectal Cancer · 2021 · Derived
PubMed: PMID 32631787 · NCT01843725 (MOMENTUM1) · Colorectal Neoplasms
RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY.
Babiuch AS, Wykoff CC, Srivastava SK, et al. · Retina · 2021 · Derived
PubMed: PMID 31917731 · NCT02863354 (RECOVERY)
Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study.
Babiuch A, Wykoff CC, Hach J, et al. · Br J Ophthalmol · 2021 · Derived
PubMed: PMID 32829304 · NCT02863354 (RECOVERY)
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Antoszyk AN, Glassman AR, Beaulieu WT, et al. · JAMA · 2021 · Derived
PubMed: PMID 33320223 · NCT02858076 (AB) · Vitreous Hemorrhage
Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Alagorie AR, Nittala MG, Velaga S, et al. · JAMA Ophthalmol · 2021 · Derived
PubMed: PMID 32584384 · NCT02863354 (RECOVERY)
Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.
Abd Elhamid AH, Mohamed AAEA, Khattab AM, et al. · BMC Ophthalmol · 2021 · Derived
PubMed: PMID 32252674 · NCT04153253
Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.
Taïeb J, André T, El Hajbi F, et al. · Dig Liver Dis · 2021 · Background
PubMed: PMID 33359404 · NCT03186326 (SAMCO) · Colorectal Neoplasms
SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.
Hendrick A, VanVeldhuisen PC, Scott IU, et al. · Am J Ophthalmol · 2021 · Background
PubMed: PMID 32828880 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Association of Severity of Dry Eye Disease with Work Productivity and Activity Impairment in the Dry Eye Assessment and Management Study.
Greco G, Pistilli M, Asbell PA, et al. · Ophthalmology · 2021 · Background
PubMed: PMID 33068617 · NCT06610747 (DME HOME) · Diabetic Retinopathy
Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis.
Garweg JG, Gerhardt C · Graefes Arch Clin Exp Ophthalmol · 2021 · Background
PubMed: PMID 33528645 · NCT04932980 (SPARROW)
Ellipsoid Zone Defects in Retinal Vein Occlusion Correlates With Visual Acuity Prognosis: SCORE2 Report 14.
Etheridge T, Dobson ETA, Wiedenmann M, et al. · Transl Vis Sci Technol · 2021 · Background
PubMed: PMID 34003964 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study.
Bilgic A, Kodjikian L, March de Ribot F, et al. · J Clin Med · 2021 · Background
PubMed: PMID 34201729 · NCT05710471 · Macular Degeneration
Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment.
Baumal CR, Bodaghi B, Singer M, et al. · Ophthalmol Retina · 2021 · Background
PubMed: PMID 33007521 · NCT05710471 · Macular Degeneration

2020 (29 papers)

EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN.
Terasaki H, Shiraki K, Ohji M, et al. · Retina · 2020 · Trial result
PubMed: PMID 29470308 · NCT04288232
Abrupt visual loss during anti-vascular endothelial growth factor treatment for type 3 neovascularization.
Kim JH, Chang YS, Kim JW, et al. · Int J Ophthalmol · 2020 · Trial result
PubMed: PMID 30918819 · NCT04655482
LONG-TERM VISUAL CHANGES IN INITIALLY STRONGER FELLOW EYES IN PATIENTS WITH UNILATERAL TYPE 3 NEOVASCULARIZATION.
Kim JH, Chang YS, Kim JW, et al. · Retina · 2020 · Trial result
PubMed: PMID 29979454 · NCT04655482
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy.
Jung BJ, Kim JY, Lee JH, et al. · Sci Rep · 2020 · Trial result
PubMed: PMID 30765771 · NCT05662410
Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study.
Yang BC, Chou TY, Chen SN, et al. · Taiwan J Ophthalmol · 2020 · Derived
PubMed: PMID 31942430 · NCT03324542 (OIVAEGFFAMDIT)
Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study.
Wykoff CC, Shah C, Dhoot D, et al. · Ophthalmology · 2020 · Derived
PubMed: PMID 30946887 · NCT01363440 (VISTA DME) · Diabetic Retinopathy
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
Strickler JH, Rushing CN, Niedzwiecki D, et al. · BMC Cancer · 2020 · Derived
PubMed: PMID 31675952 · NCT01661972 (X-TRAP) · Colorectal Neoplasms
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z, Mahroo O, Bunce C, et al. · Cochrane Database Syst Rev · 2020 · Derived
PubMed: PMID 32633861 · NCT01521559 (VIBRANT) · Retinal Vein Occlusion
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Riechelmann RP, Srimuninnimit V, Bordonaro R, et al. · Clin Colorectal Cancer · 2020 · Derived
PubMed: PMID 31221542 · NCT01571284
Emerging PEGylated non-biologic drugs.
Park EJ, Choi J, Lee KC, et al. · Expert Opin Emerg Drugs · 2020 · Derived
PubMed: PMID 30957581 · NCT01940887 · Macular Degeneration
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
Ohji M, Takahashi K, Okada AA, et al. · Adv Ther · 2020 · Derived
PubMed: PMID 32016788 · NCT02305238 (ALTAIR) · Macular Degeneration
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.
Matikas A, Souglakos J, Katsaounis P, et al. · Target Oncol · 2020 · Derived
PubMed: PMID 31203498 · NCT02624726 (MINOAS) · Colorectal Neoplasms
Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Li E, Donati S, Lindsley KB, et al. · Cochrane Database Syst Rev · 2020 · Derived
PubMed: PMID 32374423 · NCT02130024 (RIVAL) · Macular Degeneration
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Gillies MC, Hunyor AP, Arnold JJ, et al. · JAMA Ophthalmol · 2020 · Derived
PubMed: PMID 30676617 · NCT02130024 (RIVAL) · Macular Degeneration
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU, Koh A, Ogura Y, et al. · Ophthalmology · 2020 · Derived
PubMed: PMID 30986442 · NCT02307682 (HAWK) · Choroidal Neovascularization
Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study.
Chau I, Fakih M, García-Alfonso P, et al. · Cancers (Basel) · 2020 · Derived
PubMed: PMID 32168980 · NCT00561470 (VELOUR) · Colorectal Neoplasms
Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study.
Wong TY, Ogura Y, Lee WK, et al. · Am J Ophthalmol · 2020 · Background
PubMed: PMID 30849345 · NCT04075188 · Choroidal Neovascularization
LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS.
Peterson JS, Rockwell K, Scott IU, et al. · Retina · 2020 · Background
PubMed: PMID 29746405 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: The European School for Advanced Studies in Ophthalmology classification.
Panozzo G, Cicinelli MV, Augustin AJ, et al. · Eur J Ophthalmol · 2020 · Background
PubMed: PMID 31718271 · NCT05080803
Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.
Ottaiano A, Capozzi M, Tafuto S, et al. · Front Oncol · 2020 · Background
PubMed: PMID 31456948 · NCT04397601 (ARBITRATION) · Colorectal Neoplasms
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
Glassman AR, Wells JA, Josic K, et al. · Ophthalmology · 2020 · Background
PubMed: PMID 32402554 · NCT06610747 (DME HOME) · Diabetic Retinopathy
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR, Baker CW, Beaulieu WT, et al. · JAMA Ophthalmol · 2020 · Background
PubMed: PMID 32077907 · NCT01909791 (Protocol V)
Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration.
García-Quintanilla L, Luaces-Rodríguez A, Gil-Martínez M, et al. · Pharmaceutics · 2020 · Background
PubMed: PMID 31370346 · NCT04588948 (DRAW-2)
Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema.
Furino C, Boscia F, Niro A, et al. · J Ophthalmol · 2020 · Background
PubMed: PMID 28884024 · NCT03832179 (STAMP) · Cataract
A semi-automated machine-learning based workflow for ellipsoid zone analysis in eyes with macular edema: SCORE2 pilot study.
Etheridge T, Dobson ETA, Wiedenmann M, et al. · PLoS One · 2020 · Background
PubMed: PMID 32353052 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer.
Carola C, Ghiringhelli F, Kim S, et al. · World J Clin Oncol · 2020 · Background
PubMed: PMID 30254966 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial.
Bressler SB, Odia I, Maguire MG, et al. · JAMA Ophthalmol · 2020 · Background
PubMed: PMID 30676635 · NCT01627249 (Protocol T)
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Baumal CR, Spaide RF, Vajzovic L, et al. · Ophthalmology · 2020 · Background
PubMed: PMID 32344075 · NCT05710471 · Macular Degeneration
Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices.
Abràmoff MD, Lavin PT, Birch M, et al. · NPJ Digit Med · 2020 · Background
PubMed: PMID 31304320 · NCT06205979

2019 (22 papers)

Treat-and-Extend Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration: Efficacy and Macular Atrophy Development.
Matsumoto H, Morimoto M, Mimura K, et al. · Ophthalmol Retina · 2019 · Trial result
PubMed: PMID 31047326 · NCT04655482
Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis.
Kim JH, Kim JW, Kim CG, et al. · Graefes Arch Clin Exp Ophthalmol · 2019 · Trial result
PubMed: PMID 31144056 · NCT04655482
Pachychoroid disease.
Cheung CMG, Lee WK, Koizumi H, et al. · Eye (Lond) · 2019 · Trial result
PubMed: PMID 29995841 · NCT05662410
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
Baker CW, Glassman AR, Beaulieu WT, et al. · JAMA · 2019 · Trial result
PubMed: PMID 31037289 · NCT01909791 (Protocol V)
Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
Wykoff CC, Ou WC, Khurana RN, et al. · Br J Ophthalmol · 2019 · Derived
PubMed: PMID 28814412 · NCT02299336
Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
Staurenghi G, Feltgen N, Arnold JJ, et al. · Br J Ophthalmol · 2019 · Derived
PubMed: PMID 29051325 · NCT01363440 (VISTA DME) · Diabetic Retinopathy
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Ruff P, Van Cutsem E, Lakomy R, et al. · J Geriatr Oncol · 2019 · Derived
PubMed: PMID 28807738 · NCT00561470 (VELOUR) · Colorectal Neoplasms
A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.
Meehan R, Kummar S, Do K, et al. · Oncologist · 2019 · Derived
PubMed: PMID 29853657 · NCT02192541 · Neoplasms
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.
Li J, Xu R, Qin S, et al. · Future Oncol · 2019 · Derived
PubMed: PMID 30117334 · NCT01661270 (AFLAME)
Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.
Lee WK, Iida T, Ogura Y, et al. · JAMA Ophthalmol · 2019 · Derived
PubMed: PMID 29801063 · NCT02120950 (PLANET)
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Hamaguchi T, Denda T, Kudo T, et al. · Cancer Sci · 2019 · Derived
PubMed: PMID 31520559 · NCT01882868
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
Denda T, Sakai D, Hamaguchi T, et al. · Cancer Sci · 2019 · Derived
PubMed: PMID 30657223 · NCT01882868
Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study.
Wykoff CC, Ou WC, Brown DM, et al. · Ophthalmol Retina · 2019 · Background
PubMed: PMID 31047517 · NCT05710471 · Macular Degeneration
Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
Scott IU, VanVeldhuisen PC, Ip MS, et al. · JAMA Ophthalmol · 2019 · Background
PubMed: PMID 29476687 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
Reddy RK, Pieramici DJ, Gune S, et al. · Ophthalmology · 2019 · Background
PubMed: PMID 29752001 · NCT06610747 (DME HOME) · Diabetic Retinopathy
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Jampol LM, Glassman AR, Liu D, et al. · Ophthalmology · 2019 · Background
PubMed: PMID 29525602 · NCT01627249 (Protocol T)
Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.
Ip MS, Oden NL, Scott IU, et al. · JAMA Ophthalmol · 2019 · Background
PubMed: PMID 30589922 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Reply.
Glassman AR, Duh EJ, Liu D, et al. · Ophthalmology · 2019 · Background
PubMed: PMID 30318048 · NCT01627249 (Protocol T)
Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T.
Bressler NM, Beaulieu WT, Maguire MG, et al. · Am J Ophthalmol · 2019 · Background
PubMed: PMID 30077569 · NCT01627249 (Protocol T)
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM, Beaulieu WT, Glassman AR, et al. · JAMA Ophthalmol · 2019 · Background
PubMed: PMID 29392288 · NCT01627249 (Protocol T)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F, Ferlay J, Soerjomataram I, et al. · CA Cancer J Clin · 2019 · Background
PubMed: PMID 30207593 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed with a Treat-Extend-Stop Protocol.
Adrean SD, Chaili S, Grant S, et al. · Ophthalmol Retina · 2019 · Background
PubMed: PMID 31047590 · NCT06662994 · Diabetic Retinopathy

2018 (14 papers)

Changes in Choroidal Thickness After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy.
Padrón-Pérez N, Arias L, Rubio M, et al. · Invest Ophthalmol Vis Sci · 2018 · Trial result
PubMed: PMID 29490349 · NCT05662410
Early Recurrent Hemorrhage in Submacular Hemorrhage Secondary to Type 3 Neovascularization or Retinal Angiomatous Proliferation: Incidence and Influence on Visual Prognosis.
Kim JH, Chang YS, Kim JW, et al. · Semin Ophthalmol · 2018 · Trial result
PubMed: PMID 30136868 · NCT04655482
Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study.
Marques JP, Farinha C, Costa MÂ, et al. · BMJ Open · 2018 · Derived
PubMed: PMID 28851779 · NCT02495181 (ATLANTIC) · Polypoidal Choroidal Vasculopathy
Regression of Inflamed Pterygia by Frequent High-Dose Intralesional Ziv-Aflibercept.
Mansour AM · Cornea · 2018 · Derived
PubMed: PMID 28614154 · NCT02486484 (Zaltrap) · Macular Degeneration
CHOROIDAL VASCULAR HYPERPERMEABILITY AS A PREDICTOR OF TREATMENT RESPONSE FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Yanagi Y, Ting DSW, Ng WY, et al. · Retina · 2018 · Background
PubMed: PMID 28704255 · NCT04075188 · Choroidal Neovascularization
Reply.
Wells JA, Glassman AR, Jampol LM, et al. · Ophthalmology · 2018 · Background
PubMed: PMID 28219510 · NCT01627249 (Protocol T)
Reply.
Wells JA, Glassman AR, Bressler NM, et al. · Ophthalmology · 2018 · Background
PubMed: PMID 28335949 · NCT01627249 (Protocol T)
Reply.
Wells JA, Glassman AR, Ayala AR, et al. · Ophthalmology · 2018 · Background
PubMed: PMID 27993277 · NCT01627249 (Protocol T)
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
Sivaprasad S, Prevost AT, Vasconcelos JC, et al. · Lancet · 2018 · Background
PubMed: PMID 28494920 · NCT04708145 (VOYAGE) · Diabetic Retinopathy
USE OF AFLIBERCEPT FOR THE MANAGEMENT OF REFRACTORY PSEUDOPHAKIC MACULAR EDEMA IN IRVINE-GASS SYNDROME AND LITERATURE REVIEW.
Lin CJ, Tsai YY · Retin Cases Brief Rep · 2018 · Background
PubMed: PMID 27617392 · NCT03396861 (ACME) · Macular Edema
Association Between Soluble CD14 in the Aqueous Humor and Hyperreflective Foci on Optical Coherence Tomography in Patients With Diabetic Macular Edema.
Lee H, Jang H, Choi YA, et al. · Invest Ophthalmol Vis Sci · 2018 · Background
PubMed: PMID 29392317 · NCT03780361 (FORESIGHT)
Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Glassman AR, Liu D, Jampol LM, et al. · Invest Ophthalmol Vis Sci · 2018 · Background
PubMed: PMID 29625440 · NCT01627249 (Protocol T)
EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY.
Calvo P, Ferreras A, Al Adel F, et al. · Retina · 2018 · Background
PubMed: PMID 28196056 · NCT03832179 (STAMP) · Cataract
Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema-Reply.
Bressler NM, Glassman AR, Hutton DW, et al. · JAMA Ophthalmol · 2018 · Background
PubMed: PMID 28152135 · NCT01627249 (Protocol T)

2017 (40 papers)

AN UPDATED STAGING SYSTEM OF TYPE 3 NEOVASCULARIZATION USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY.
Su D, Lin S, Phasukkijwatana N, et al. · Retina · 2017 · Trial result
PubMed: PMID 28005662 · NCT04655482
Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model.
Sella R, Gal-Or O, Livny E, et al. · Exp Eye Res · 2017 · Trial result
PubMed: PMID 27020759 · NCT02797704 · Corneal Neovascularization
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
Scott IU, VanVeldhuisen PC, Ip MS, et al. · JAMA · 2017 · Trial result
PubMed: PMID 28492910 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION.
Matsumoto H, Sato T, Morimoto M, et al. · Retina · 2017 · Trial result
PubMed: PMID 27336229 · NCT04655482
Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.
Mansour AM, Chhablani J, Antonios RS, et al. · Br J Ophthalmol · 2017 · Trial result
PubMed: PMID 27030277 · NCT02486484 (Zaltrap) · Macular Degeneration
Incidence and risk factors of massive subretinal hemorrhage in retinal angiomatous proliferation.
Lee JH, Lee MY, Lee WK, et al. · PLoS One · 2017 · Trial result
PubMed: PMID 29023498 · NCT04655482
Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study.
Kim JH, Lee TG, Chang YS, et al. · Br J Ophthalmol · 2017 · Trial result
PubMed: PMID 26951770 · NCT05662410
Efficacy of Subconjunctival Aflibercept Versus Bevacizumab for Prevention of Corneal Neovascularization in a Rat Model.
Gal-Or O, Livny E, Sella R, et al. · Cornea · 2017 · Trial result
PubMed: PMID 27124775 · NCT02797704 · Corneal Neovascularization
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Folprecht G, Pericay C, Saunders MP, et al. · Ann Oncol · 2017 · Trial result
PubMed: PMID 27091810 · NCT00851084 (AFFIRM) · Colorectal Neoplasms
One-Year Outcomes of the Treat-and-Extend Approach with Aflibercept in Age-Related Macular Degeneration: Effects on Typical Choroidal Neovascularization and Retinal Angiomatous Proliferation.
Castro-Navarro V, Cervera-Taulet E, Montero-Hernández J, et al. · Ophthalmologica · 2017 · Trial result
PubMed: PMID 27997921 · NCT04655482
Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
Abdelfattah NS, Al-Sheikh M, Pitetta S, et al. · Ophthalmology · 2017 · Trial result
PubMed: PMID 27863845 · NCT04655482
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Van Cutsem E, Joulain F, Hoff PM, et al. · Target Oncol · 2017 · Derived
PubMed: PMID 26706237 · NCT00561470 (VELOUR) · Colorectal Neoplasms
Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
Kokame GT, Lai JC, Wee R, et al. · BMC Ophthalmol · 2017 · Derived
PubMed: PMID 27465105 · NCT01871376 (EPIC) · Polypoidal Choroidal Vasculopathy
Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.
Jeong S, Sagong M · Br J Ophthalmol · 2017 · Derived
PubMed: PMID 27597740 · NCT02597855 · Polypoidal Choroidal Vasculopathy
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU, Jaffe GJ, Sallstig P, et al. · Ophthalmology · 2017 · Derived
PubMed: PMID 28551167 · NCT01796964 · Macular Degeneration
Optical Coherence Tomography Angiography in Central Retinal Vein Occlusion: Correlation Between the Foveal Avascular Zone and Visual Acuity.
Casselholmde Salles M, Kvanta A, Amrén U, et al. · Invest Ophthalmol Vis Sci · 2017 · Derived
PubMed: PMID 27409478 · NCT02274259 · Retinal Vein Occlusion
Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
Wykoff CC, Le RT, Khurana RN, et al. · Am J Ophthalmol · 2017 · Background
PubMed: PMID 27702624 · NCT04708145 (VOYAGE) · Diabetic Retinopathy
Orbital Angiogenesis and Lymphangiogenesis in Thyroid Eye Disease: An Analysis of Vascular Growth Factors with Clinical Correlation.
Wong LL, Lee NG, Amarnani D, et al. · Ophthalmology · 2017 · Background
PubMed: PMID 27423310 · NCT04311606 (AcTED) · Graves Ophthalmopathy
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA, Glassman AR, Ayala AR, et al. · Ophthalmology · 2017 · Background
PubMed: PMID 26935357 · NCT01627249 (Protocol T)
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M, Todorova MG, Masyk M, et al. · BMC Ophthalmol · 2017 · Background
PubMed: PMID 28535756 · NCT05710471 · Macular Degeneration
Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ, Kahaly GJ, Ezra DG, et al. · N Engl J Med · 2017 · Background
PubMed: PMID 28467880 · NCT04311606 (AcTED) · Graves Ophthalmopathy
Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU, VanVeldhuisen PC, Ip MS, et al. · JAMA Ophthalmol · 2017 · Background
PubMed: PMID 28492860 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion.
Scott IU, VanVeldhuisen PC, Ip MS, et al. · Am J Ophthalmol · 2017 · Background
PubMed: PMID 27450625 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
SCORE2 Report 2: Study Design and Baseline Characteristics.
Scott IU, VanVeldhuisen PC, Ip MS, et al. · Ophthalmology · 2017 · Background
PubMed: PMID 27863843 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.
Scott IU, Figueroa MJ, Oden NL, et al. · Am J Ophthalmol · 2017 · Background
PubMed: PMID 29074161 · NCT01969708 (SCORE2) · Retinal Vein Occlusion
Insulin resistance is associated with tissue-specific regulation of HIF-1α and HIF-2α during mild chronic intermittent hypoxia.
Sacramento JF, Ribeiro MJ, Rodrigues T, et al. · Respir Physiol Neurobiol · 2017 · Background
PubMed: PMID 26993367 · NCT03597815 (DME-OSA) · Sleep Apnea Syndromes
Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
Ross EL, Hutton DW, Stein JD, et al. · JAMA Ophthalmol · 2017 · Background
PubMed: PMID 27280850 · NCT01627249 (Protocol T)
Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery - preliminary 6 month results.
Lim LL, Morrison JL, Constantinou M, et al. · Clin Exp Ophthalmol · 2017 · Background
PubMed: PMID 26871700 · NCT03832179 (STAMP) · Cataract
Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010.
Leasher JL, Bourne RR, Flaxman SR, et al. · Diabetes Care · 2017 · Background
PubMed: PMID 27555623 · NCT03531294 · Diabetic Retinopathy
Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
Laugesen CS, Ostri C, Brynskov T, et al. · Acta Ophthalmol · 2017 · Background
PubMed: PMID 27473397 · NCT06662994 · Diabetic Retinopathy
Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
Koh A, Lai TYY, Takahashi K, et al. · JAMA Ophthalmol · 2017 · Background
PubMed: PMID 28983556 · NCT04075188 · Choroidal Neovascularization
Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.
Kitchens JW, Do DV, Boyer DS, et al. · Ophthalmology · 2017 · Background
PubMed: PMID 27084563 · NCT03396861 (ACME) · Macular Edema
Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma.
Kim IK, Lane AM, Jain P, et al. · Trans Am Ophthalmol Soc · 2017 · Background
PubMed: PMID 27630373 · NCT03085784 (ARRT)
Ranibizumab for persistent diabetic macular edema after bevacizumab treatment.
Katz G, Moisseiev E, Goldenberg D, et al. · Eur J Ophthalmol · 2017 · Background
PubMed: PMID 27445070 · NCT06205979
Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
Jampol LM, Glassman AR, Bressler NM, et al. · JAMA Ophthalmol · 2017 · Background
PubMed: PMID 27711918 · NCT01627249 (Protocol T)
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS, Korobelnik JF, Brown DM, et al. · Ophthalmology · 2017 · Background
PubMed: PMID 27651226 · NCT06610747 (DME HOME) · Diabetic Retinopathy
Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs.
Gulshan V, Peng L, Coram M, et al. · JAMA · 2017 · Background
PubMed: PMID 27898976 · NCT03531294 · Diabetic Retinopathy
Automated quantitative characterisation of retinal vascular leakage and microaneurysms in ultra-widefield fluorescein angiography.
Ehlers JP, Wang K, Vasanji A, et al. · Br J Ophthalmol · 2017 · Background
PubMed: PMID 28432113 · NCT03531294 · Diabetic Retinopathy
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB, Liu D, Glassman AR, et al. · JAMA Ophthalmol · 2017 · Background
PubMed: PMID 28448655 · NCT04708145 (VOYAGE) · Diabetic Retinopathy
Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature.
Ashraf M, Souka A, Adelman R, et al. · Br J Ophthalmol · 2017 · Background
PubMed: PMID 27231313 · NCT06205979

2016 (27 papers)

Inhibitory Effect of Topical Aflibercept on Corneal Neovascularization in Rabbits.
Park YR, Chung SK · Cornea · 2016 · Trial result
PubMed: PMID 26114826 · NCT02797704 · Corneal Neovascularization
Long-term Outcomes After Preoperative Intravitreal Injection of Bevacizumab Before Trabeculectomy for Neovascular Glaucoma.
Kobayashi S, Inoue M, Yamane S, et al. · J Glaucoma · 2016 · Trial result
PubMed: PMID 25580888 · NCT04970251 · Glaucoma, Neovascular
TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.
Freund KB, Korobelnik JF, Devenyi R, et al. · Retina · 2016 · Trial result
PubMed: PMID 26076215 · NCT04655482
Fellow-eye neovascularization in unilateral retinal angiomatous proliferation in a Korean population.
Chang YS, Kim JH, Yoo SJ, et al. · Acta Ophthalmol · 2016 · Trial result
PubMed: PMID 25981599 · NCT04655482
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ, Templeton AJ, Vera-Badillo FE, et al. · Ann Oncol · 2016 · Derived
PubMed: PMID 25515657 · NCT00519285 (VENICE) · Neoplasm Metastasis
Intravitreal Aflibercept for Neovascular AMD: Short-Term Clinical Effects of Intravitreal Aflibercept Injection as a Predictor of Long-Term Results.
Liu EM, Shah G, Blinder KJ, et al. · Ophthalmic Surg Lasers Imaging Retina · 2016 · Derived
PubMed: PMID 26599244 · NCT01657669 · Macular Degeneration
Comparison of Perioperative Ranibizumab Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery.
Yumuşak E, Örnek K · J Ophthalmol · 2016 · Background
PubMed: PMID 27493795 · NCT03832179 (STAMP) · Cataract
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Wells JA, Glassman AR, Jampol LM, et al. · JAMA Ophthalmol · 2016 · Background
PubMed: PMID 26605836 · NCT01627249 (Protocol T)
Functional outcome of macular edema in different retinal disorders.
Tomkins-Netzer O, Ismetova F, Bar A, et al. · Prog Retin Eye Res · 2016 · Background
PubMed: PMID 26014685 · NCT03651011 (NIRVANA) · Macular Edema
Diabetic Retinopathy Severity and Peripheral Lesions Are Associated with Nonperfusion on Ultrawide Field Angiography.
Silva PS, Dela Cruz AJ, Ledesma MG, et al. · Ophthalmology · 2016 · Background
PubMed: PMID 26350546 · NCT03006081 · Diabetic Retinopathy
Subconjunctival Bevacizumab for the Treatment of Keratoprosthesis-Associated Cystoid Macular Edema.
Muakkassa NW, Klein KA, Hamrah P, et al. · Ophthalmic Surg Lasers Imaging Retina · 2016 · Background
PubMed: PMID 26985802 · NCT03396861 (ACME) · Macular Edema
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF SUBRETINAL FIBROSIS IN AGE-RELATED MACULAR DEGENERATION.
Miere A, Semoun O, Cohen SY, et al. · Retina · 2016 · Background
PubMed: PMID 26457397 · NCT03022292 (IAI-OCTA) · Wet Macular Degeneration
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN EARLY TYPE 3 NEOVASCULARIZATION.
Miere A, Querques G, Semoun O, et al. · Retina · 2016 · Background
PubMed: PMID 26457399 · NCT03022292 (IAI-OCTA) · Wet Macular Degeneration
Study of retinal vessel oxygen saturation in ischemic and non-ischemic branch retinal vein occlusion.
Lin LL, Dong YM, Zong Y, et al. · Int J Ophthalmol · 2016 · Background
PubMed: PMID 26949618 · NCT03651011 (NIRVANA) · Macular Edema
Effect of obstructive sleep apnoea on diabetic retinopathy and maculopathy: a systematic review and meta-analysis.
Leong WB, Jadhakhan F, Taheri S, et al. · Diabet Med · 2016 · Background
PubMed: PMID 26031931 · NCT03597815 (DME-OSA) · Sleep Apnea Syndromes
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF TYPE 3 NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kuehlewein L, Dansingani KK, de Carlo TE, et al. · Retina · 2016 · Background
PubMed: PMID 26502007 · NCT03022292 (IAI-OCTA) · Wet Macular Degeneration
Transforming growth factor β1 (TGFβ1) and vascular endothelial growth factor (VEGF) in the blood of healthy people and patients with Graves' orbitopathy--a new mechanism of glucocorticoids action?
Kajdaniuk D, Marek B, Niedziołka-Zielonka D, et al. · Endokrynol Pol · 2016 · Background
PubMed: PMID 25301484 · NCT04311606 (AcTED) · Graves Ophthalmopathy
Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.
Ghiringhelli F, Vincent J, Beltjens F, et al. · Invest New Drugs · 2016 · Background
PubMed: PMID 26490656 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
TYPE 2 NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION IMAGED BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.
El Ameen A, Cohen SY, Semoun O, et al. · Retina · 2016 · Background
PubMed: PMID 26441269 · NCT03022292 (IAI-OCTA) · Wet Macular Degeneration
Optical coherence tomography angiography during follow-up: qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therapy.
Coscas G, Lupidi M, Coscas F, et al. · Ophthalmic Res · 2016 · Background
PubMed: PMID 26201877 · NCT03022292 (IAI-OCTA) · Wet Macular Degeneration
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
Clark WL, Boyer DS, Heier JS, et al. · Ophthalmology · 2016 · Background
PubMed: PMID 26522708 · NCT03651011 (NIRVANA) · Macular Edema
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
Chibaudel B, Maindrault-Gœbel F, Bachet JB, et al. · Cancer Med · 2016 · Background
PubMed: PMID 26806397 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Bressler SB, Melia M, Glassman AR, et al. · Retina · 2016 · Background
PubMed: PMID 26035510 · NCT06662994 · Diabetic Retinopathy
Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
Bressler SB, Ayala AR, Bressler NM, et al. · JAMA Ophthalmol · 2016 · Background
PubMed: PMID 26746868 · NCT06205979
Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting.
Boulanger-Scemama E, Querques G, About F, et al. · J Fr Ophtalmol · 2016 · Background
PubMed: PMID 25913443 · NCT05710471 · Macular Degeneration
Polypoidal Choroidal Vasculopathy: A Distinct Disease or Manifestation of Many?
Balaratnasingam C, Lee WK, Koizumi H, et al. · Retina · 2016 · Background
PubMed: PMID 26414957 · NCT04075188 · Choroidal Neovascularization
Experience of intravitreal injections in a tertiary Hospital in Oman.
Al-Hinai AS · Oman J Ophthalmol · 2016 · Background
PubMed: PMID 26903722 · NCT04588948 (DRAW-2)

2015 (39 papers)

A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis.
Singh RP, Srivastava SK, Ehlers JP, et al. · Clin Ophthalmol · 2015 · Trial result
PubMed: PMID 26445522 · NCT01617148 · Wet Macular Degeneration
Pachychoroid neovasculopathy.
Pang CE, Freund KB · Retina · 2015 · Trial result
PubMed: PMID 25158945 · NCT05662410
Ziv-aflibercept in macular disease.
Mansour AM, Al-Ghadban SI, Yunis MH, et al. · Br J Ophthalmol · 2015 · Trial result
PubMed: PMID 25677668 · NCT02486484 (Zaltrap) · Macular Degeneration
Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. · Ophthalmology · 2015 · Trial result
PubMed: PMID 25012934 · NCT04288232
A Prospective Study to Evaluate Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma.
Kitnarong N, Sriyakul C, Chinwattanakul S, et al. · Ophthalmol Ther · 2015 · Trial result
PubMed: PMID 25812531 · NCT04970251 · Glaucoma, Neovascular
Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
Grunwald JE, Pistilli M, Ying GS, et al. · Ophthalmology · 2015 · Trial result
PubMed: PMID 25542520 · NCT04655482
Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.
Elman MJ, Ayala A, Bressler NM, et al. · Ophthalmology · 2015 · Trial result
PubMed: PMID 25439614 · NCT06610747 (DME HOME) · Diabetic Retinopathy
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. · N Engl J Med · 2015 · Trial result
PubMed: PMID 25692915 · NCT01627249 (Protocol T)
Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration.
de Oliveira Dias JR, Xavier CO, Maia A, et al. · Ophthalmic Surg Lasers Imaging Retina · 2015 · Trial result
PubMed: PMID 25559518 · NCT02556723 · Macular Degeneration
Preclinical investigations of intravitreal ziv-aflibercept.
de Oliveira Dias JR, Badaró E, Novais EA, et al. · Ophthalmic Surg Lasers Imaging Retina · 2015 · Trial result
PubMed: PMID 25423640 · NCT02556723 · Macular Degeneration
Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
Yuzawa M, Fujita K, Wittrup-Jensen KU, et al. · Ophthalmology · 2015 · Derived
PubMed: PMID 25439429 · NCT00637377 (VIEW 2) · Macular Degeneration
A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study.
Pitcher JD, Witkin AJ, DeCroos FC, et al. · Br J Ophthalmol · 2015 · Derived
PubMed: PMID 25595177 · NCT01710332 (CONTAIN) · Central Serous Chorioretinopathy
Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study.
Ogura Y, Terasaki H, Gomi F, et al. · Br J Ophthalmol · 2015 · Derived
PubMed: PMID 25107900 · NCT00637377 (VIEW 2) · Macular Degeneration
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Lara PN, Moon J, Redman MW, et al. · J Thorac Oncol · 2015 · Derived
PubMed: PMID 25490004 · NCT00828139 · Small Cell Lung Carcinoma
Phase I dose-escalation study of aflibercept plus docetaxel in nasopharyngeal carcinoma and other solid tumors.
Huang Y, Zou BY, Zhao LP, et al. · Future Oncol · 2015 · Derived
PubMed: PMID 25531046 · NCT01148615 · Neoplasms
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.
Avery RL, Castellarin AA, Steinle NC, et al. · Br J Ophthalmol · 2015 · Derived
PubMed: PMID 25001321 · NCT02118831 · Macular Degeneration
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. · JAMA · 2015 · Background
PubMed: PMID 26565927 · NCT04708145 (VOYAGE) · Diabetic Retinopathy
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wong WL, Su X, Li X, et al. · Lancet Glob Health · 2015 · Background
PubMed: PMID 25104651 · NCT05710471 · Macular Degeneration
Targeting the Effect of VEGF in Diabetic Macular Edema.
Wells JA, Glassman AR, Jampol LM, et al. · N Engl J Med · 2015 · Background
PubMed: PMID 26222565 · NCT01627249 (Protocol T)
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, et al. · Lancet Oncol · 2015 · Background
PubMed: PMID 25877855 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Optical Coherence Tomography Angiography Signs of Vascular Abnormalization With Antiangiogenic Therapy for Choroidal Neovascularization.
Spaide RF · Am J Ophthalmol · 2015 · Background
PubMed: PMID 25887628 · NCT03022292 (IAI-OCTA) · Wet Macular Degeneration
Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion.
Singer M, Tan CS, Bell D, et al. · Retina · 2015 · Background
PubMed: PMID 24732695 · NCT02503540 (PERMEATE) · Macular Edema
Peripheral Lesions Identified on Ultrawide Field Imaging Predict Increased Risk of Diabetic Retinopathy Progression over 4 Years.
Silva PS, Cavallerano JD, Haddad NM, et al. · Ophthalmology · 2015 · Background
PubMed: PMID 25704318 · NCT03006081 · Diabetic Retinopathy
Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.
Pielen A, Mirshahi A, Feltgen N, et al. · Acta Ophthalmol · 2015 · Background
PubMed: PMID 25042729 · NCT03651011 (NIRVANA) · Macular Edema
Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
Ogura Y, Roider J, Korobelnik JF, et al. · Am J Ophthalmol · 2015 · Background
PubMed: PMID 25068637 · NCT04707625 · Retinal Vein Occlusion
Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema.
Liegl R, Langer J, Seidensticker F, et al. · PLoS One · 2015 · Background
PubMed: PMID 25541960 · NCT03651011 (NIRVANA) · Macular Edema
Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration.
Kuehlewein L, Bansal M, Lenis TL, et al. · Am J Ophthalmol · 2015 · Background
PubMed: PMID 26164826 · NCT03022292 (IAI-OCTA) · Wet Macular Degeneration
Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
Jampol LM, Glassman AR, Bressler NM, et al. · JAMA Ophthalmol · 2015 · Background
PubMed: PMID 26087135 · NCT01627249 (Protocol T)
Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS, Domalpally A, Sun JK, et al. · Ophthalmology · 2015 · Background
PubMed: PMID 25439595 · NCT03531294 · Diabetic Retinopathy
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.
Holz FG, Tadayoni R, Beatty S, et al. · Br J Ophthalmol · 2015 · Background
PubMed: PMID 25193672 · NCT05710471 · Macular Degeneration
Management of pseudophakic cystoid macular edema.
Guo S, Patel S, Baumrind B, et al. · Surv Ophthalmol · 2015 · Background
PubMed: PMID 25438734 · NCT03396861 (ACME) · Macular Edema
High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy.
Finger PT, Chin KJ · Eur J Ophthalmol · 2015 · Background
PubMed: PMID 23813109 · NCT03085784 (ARRT)
Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery.
Dong N, Xu B, Wang B, et al. · Biomed Res Int · 2015 · Background
PubMed: PMID 25811020 · NCT03832179 (STAMP) · Cataract
Precise montaging and metric quantification of retinal surface area from ultra-widefield fundus photography and fluorescein angiography.
Croft DE, van Hemert J, Wykoff CC, et al. · Ophthalmic Surg Lasers Imaging Retina · 2015 · Background
PubMed: PMID 25037013 · NCT03531294 · Diabetic Retinopathy
Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study.
Campochiaro PA, Wykoff CC, Singer M, et al. · Ophthalmology · 2015 · Background
PubMed: PMID 25060610 · NCT02863354 (RECOVERY)
Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM, Schmidt-Erfurth U, Do DV, et al. · Ophthalmology · 2015 · Background
PubMed: PMID 26198808 · NCT03531294 · Diabetic Retinopathy
Causes of vision loss worldwide, 1990-2010: a systematic analysis.
Bourne RR, Stevens GA, White RA, et al. · Lancet Glob Health · 2015 · Background
PubMed: PMID 25104599 · NCT04708145 (VOYAGE) · Diabetic Retinopathy
Anaemia, a common but often unrecognized risk in diabetic patients: a review.
Angelousi A, Larger E · Diabetes Metab · 2015 · Background
PubMed: PMID 25043174 · NCT04288232
Erratum. Intraocular Pharmacokinetics of Ranibizumab in Vitrectomized Versus Nonvitrectomized Eyes.
Ahn SJ, Ahn J, Park S, et al. · Invest Ophthalmol Vis Sci · 2015 · Background
PubMed: PMID 25737148 · NCT04588948 (DRAW-2)

2014 (26 papers)

Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.
Tew WP, Colombo N, Ray-Coquard I, et al. · Cancer · 2014 · Trial result
PubMed: PMID 24127346 · NCT00327171 · Neoplasms
A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis.
Singh RP, Srivastava S, Ehlers JP, et al. · Br J Ophthalmol · 2014 · Trial result
PubMed: PMID 24836866 · NCT01617148 · Wet Macular Degeneration
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. · Ophthalmology · 2014 · Trial result
PubMed: PMID 24084500 · NCT00637377 (VIEW 2) · Macular Degeneration
Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
Korobelnik JF, Holz FG, Roider J, et al. · Ophthalmology · 2014 · Trial result
PubMed: PMID 24084497 · NCT01012973 (GALILEO) · Macular Edema
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
Grunwald JE, Daniel E, Huang J, et al. · Ophthalmology · 2014 · Trial result
PubMed: PMID 24084496 · NCT04655482
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.
Chen H, Modiano MR, Neal JW, et al. · Br J Cancer · 2014 · Trial result
PubMed: PMID 24292447 · NCT00794417 · Lung Neoplasms
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Yoshino T, Yamazaki K, Yamaguchi K, et al. · Invest New Drugs · 2014 · Derived
PubMed: PMID 23179335 · NCT00921661 · Colorectal Neoplasms
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
Wykoff CC, Brown DM, Maldonado ME, et al. · Br J Ophthalmol · 2014 · Derived
PubMed: PMID 24518078 · NCT01543568 (TURF) · Macular Degeneration
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Tabernero J, Van Cutsem E, Lakomý R, et al. · Eur J Cancer · 2014 · Derived
PubMed: PMID 24140268 · NCT00561470 (VELOUR) · Colorectal Neoplasms
Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer.
de Liaño AG, Reig O, Mellado B, et al. · Br J Cancer · 2014 · Derived
PubMed: PMID 24722180 · NCT00519285 (VENICE) · Neoplasm Metastasis
Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.
Allen JW, Moon J, Redman M, et al. · J Clin Oncol · 2014 · Derived
PubMed: PMID 25002722 · NCT00828139 · Small Cell Lung Carcinoma
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD, Lindsley K, Vedula SS, et al. · Cochrane Database Syst Rev · 2014 · Background
PubMed: PMID 25170575 · NCT03022292 (IAI-OCTA) · Wet Macular Degeneration
Aflibercept in wet AMD: specific role and optimal use.
Semeraro F, Morescalchi F, Duse S, et al. · Drug Des Devel Ther · 2014 · Background
PubMed: PMID 23990705 · NCT02797704 · Corneal Neovascularization
Investigation of neutrophil lymphocyte ratio and blood glucose regulation in patients with type 2 diabetes mellitus.
Sefil F, Ulutas KT, Dokuyucu R, et al. · J Int Med Res · 2014 · Background
PubMed: PMID 24567354 · NCT04288232
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).
Schmidt-Erfurth U, Chong V, Loewenstein A, et al. · Br J Ophthalmol · 2014 · Background
PubMed: PMID 25136079 · NCT05710471 · Macular Degeneration
Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
Malik D, Tarek M, Caceres del Carpio J, et al. · Br J Ophthalmol · 2014 · Background
PubMed: PMID 24836865 · NCT02173873 (ZIV) · Macular Degeneration
Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration.
Jia Y, Bailey ST, Wilson DJ, et al. · Ophthalmology · 2014 · Background
PubMed: PMID 24679442 · NCT03022292 (IAI-OCTA) · Wet Macular Degeneration
Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
Heier JS, Clark WL, Boyer DS, et al. · Ophthalmology · 2014 · Background
PubMed: PMID 24679444 · NCT04707625 · Retinal Vein Occlusion
Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration.
Fauser S, Schwabecker V, Muether PS, et al. · Am J Ophthalmol · 2014 · Background
PubMed: PMID 24879948 · NCT04932980 (SPARROW)
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.
Falavarjani KG, Nguyen QD · Eye (Lond) · 2014 · Background
PubMed: PMID 23722722 · NCT04707625 · Retinal Vein Occlusion
Prevalence, racial variations, and risk factors of age-related macular degeneration in Singaporean Chinese, Indians, and Malays.
Cheung CM, Li X, Cheng CY, et al. · Ophthalmology · 2014 · Background
PubMed: PMID 24661862 · NCT05710471 · Macular Degeneration
Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema.
Campochiaro PA, Wykoff CC, Shapiro H, et al. · Ophthalmology · 2014 · Background
PubMed: PMID 24768239 · NCT03006081 · Diabetic Retinopathy
Correlation of neutrophil to lymphocyte ratio with the presence and severity of metabolic syndrome.
Buyukkaya E, Karakas MF, Karakas E, et al. · Clin Appl Thromb Hemost · 2014 · Background
PubMed: PMID 22992349 · NCT04288232
Retinal vessel calibers predict long-term microvascular complications in type 1 diabetes: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987).
Broe R, Rasmussen ML, Frydkjaer-Olsen U, et al. · Diabetes · 2014 · Background
PubMed: PMID 24914239 · NCT03651011 (NIRVANA) · Macular Edema
The potential association between obstructive sleep apnea and diabetic retinopathy in severe obesity-the role of hypoxemia.
Banerjee D, Leong WB, Arora T, et al. · PLoS One · 2014 · Background
PubMed: PMID 24260240 · NCT03597815 (DME-OSA) · Sleep Apnea Syndromes
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.
Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, et al. · JAMA Ophthalmol · 2014 · Background
PubMed: PMID 24310343 · NCT03712670 · Retinal Diseases

2013 (20 papers)

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
Wang-Gillam A, Tew WP, Rothenberg ML, et al. · Invest New Drugs · 2013 · Trial result
PubMed: PMID 22002018 · NCT00082823 · Neoplasms
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF, Fizazi K, Ivanov S, et al. · Lancet Oncol · 2013 · Trial result
PubMed: PMID 23742877 · NCT00519285 (VENICE) · Neoplasm Metastasis
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
Rougier P, Riess H, Manges R, et al. · Eur J Cancer · 2013 · Trial result
PubMed: PMID 23642329 · NCT00574275 (VANILLA) · Pancreatic Neoplasms
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
Maison-Blanche P, Vermorken JB, Goksel T, et al. · J Cardiovasc Pharmacol · 2013 · Trial result
PubMed: PMID 23429593 · NCT00876044 (QUTIE) · Neoplasms
VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.
Holz FG, Roider J, Ogura Y, et al. · Br J Ophthalmol · 2013 · Trial result
PubMed: PMID 23298885 · NCT01012973 (GALILEO) · Macular Edema
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS, Brown DM, Chong V, et al. · Ophthalmology · 2013 · Trial result
PubMed: PMID 23084240 · NCT00637377 (VIEW 2) · Macular Degeneration
The effects of aflibercept on the viability and metabolism of ocular cells in vitro.
Ammar DA, Mandava N, Kahook MY, et al. · Retina · 2013 · Trial result
PubMed: PMID 23266881 · NCT03313401 · Macular Degeneration
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Coleman RL, Sill MW, Lankes HA, et al. · Gynecol Oncol · 2013 · Derived
PubMed: PMID 22922531 · NCT00462826 · Endometrial Neoplasms
Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy.
Semeraro F, Romano MR, Danzi P, et al. · Jpn J Ophthalmol · 2013 · Background
PubMed: PMID 22915299 · NCT01971190 · Central Serous Chorioretinopathy
Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema.
Rauen PI, Ribeiro JA, Almeida FP, et al. · Retina · 2013 · Background
PubMed: PMID 22495327 · NCT03832179 (STAMP) · Cataract
High prevalence of sleep disordered breathing in patients with diabetic macular edema.
Mason RH, West SD, Kiire CA, et al. · Retina · 2013 · Background
PubMed: PMID 22714043 · NCT03597815 (DME-OSA) · Sleep Apnea Syndromes
Visual improvement following continuous positive airway pressure therapy in diabetic subjects with clinically significant macular oedema and obstructive sleep apnoea: proof of principle study.
Mason RH, Kiire CA, Groves DC, et al. · Respiration · 2013 · Background
PubMed: PMID 22189259 · NCT03597815 (DME-OSA) · Sleep Apnea Syndromes
Oxygen saturation in branch retinal vein occlusion.
Hardarson SH, Stefánsson E · Acta Ophthalmol · 2013 · Background
PubMed: PMID 21518303 · NCT03651011 (NIRVANA) · Macular Edema
Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.
Frampton JE · Drugs Aging · 2013 · Background
PubMed: PMID 23038609 · NCT01971190 · Central Serous Chorioretinopathy
Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy.
Christoforidis JB, Williams MM, Wang J, et al. · Retina · 2013 · Background
PubMed: PMID 23407351 · NCT06662994 · Diabetic Retinopathy
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
Brown DM, Nguyen QD, Marcus DM, et al. · Ophthalmology · 2013 · Background
PubMed: PMID 23706949 · NCT04708145 (VOYAGE) · Diabetic Retinopathy
Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
Brown DM, Heier JS, Clark WL, et al. · Am J Ophthalmol · 2013 · Background
PubMed: PMID 23218699 · NCT01971190 · Central Serous Chorioretinopathy
Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
Bottsford-Miller JN, Coleman RL, Sood AK, et al. · J Clin Oncol · 2013 · Background
PubMed: PMID 23008289 · NCT02192541 · Neoplasms
Anterior segment uses of bevacizumab.
Bahar I, Yeung SN, Sella R, et al. · Curr Opin Ophthalmol · 2013 · Background
PubMed: PMID 22634640 · NCT03396861 (ACME) · Macular Edema
The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1).
AREDS2 Research Group, Chew EY, Clemons T, et al. · Ophthalmology · 2013 · Background
PubMed: PMID 22840421 · NCT03712670 · Retinal Diseases

2012 (25 papers)

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R, Gorbunova V, Ciuleanu TE, et al. · J Clin Oncol · 2012 · Trial result
PubMed: PMID 22965962 · NCT00532155 (VITAL) · Lung Neoplasms
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Nguyen QD, Brown DM, Marcus DM, et al. · Ophthalmology · 2012 · Trial result
PubMed: PMID 22330964 · NCT02556723 · Macular Degeneration
One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.
Do DV, Nguyen QD, Boyer D, et al. · Ophthalmology · 2012 · Trial result
PubMed: PMID 22537617 · NCT04288232
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.
Diaz-Padilla I, Siu LL, San Pedro-Salcedo M, et al. · Br J Cancer · 2012 · Trial result
PubMed: PMID 22805331 · NCT00794417 · Lung Neoplasms
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E, Tabernero J, Lakomy R, et al. · J Clin Oncol · 2012 · Derived
PubMed: PMID 22949147 · NCT00561470 (VELOUR) · Colorectal Neoplasms
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Gotlieb WH, Amant F, Advani S, et al. · Lancet Oncol · 2012 · Derived
PubMed: PMID 22192729 · NCT00327444 · Ovarian Neoplasms
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
Colombo N, Mangili G, Mammoliti S, et al. · Gynecol Oncol · 2012 · Derived
PubMed: PMID 22112608 · NCT00396591 · Ovarian Neoplasms
Retinal vessel caliber and risk factors for branch retinal vein occlusion.
Youm DJ, Ha MM, Chang Y, et al. · Curr Eye Res · 2012 · Background
PubMed: PMID 22324736 · NCT03651011 (NIRVANA) · Macular Edema
Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema.
Wessel MM, Nair N, Aaker GD, et al. · Br J Ophthalmol · 2012 · Background
PubMed: PMID 22423055 · NCT02559180 (SwapTwo) · Diabetic Retinopathy
Aflibercept in the treatment of metastatic colorectal cancer.
Wang TF, Lockhart AC · Clin Med Insights Oncol · 2012 · Background
PubMed: PMID 22253552 · NCT02045030 · Colorectal Neoplasms
Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).
Stevenson W, Cheng SF, Dastjerdi MH, et al. · Ocul Surf · 2012 · Background
PubMed: PMID 22482468 · NCT02797704 · Corneal Neovascularization
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.
Papadopoulos N, Martin J, Ruan Q, et al. · Angiogenesis · 2012 · Background
PubMed: PMID 22302382 · NCT03396861 (ACME) · Macular Edema
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.
Ohr M, Kaiser PK · Expert Opin Pharmacother · 2012 · Background
PubMed: PMID 22300011 · NCT01543568 (TURF) · Macular Degeneration
EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
Koh A, Lee WK, Chen LJ, et al. · Retina · 2012 · Background
PubMed: PMID 22426346 · NCT01950741 (VAULT) · Polypoidal Choroidal Vasculopathy
Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys.
Kakinoki M, Sawada O, Sawada T, et al. · Invest Ophthalmol Vis Sci · 2012 · Background
PubMed: PMID 22836776 · NCT04588948 (DRAW-2)
Long-term effects of ranibizumab on diabetic retinopathy severity and progression.
Ip MS, Domalpally A, Hopkins JJ, et al. · Arch Ophthalmol · 2012 · Background
PubMed: PMID 22965590 · NCT02863354 (RECOVERY)
Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
Heier JS, Campochiaro PA, Yau L, et al. · Ophthalmology · 2012 · Background
PubMed: PMID 22301066 · NCT01870427 (NEWTON) · Macular Edema
Retinal vessel oxygen saturation in healthy individuals.
Geirsdottir A, Palsson O, Hardarson SH, et al. · Invest Ophthalmol Vis Sci · 2012 · Background
PubMed: PMID 22786895 · NCT03651011 (NIRVANA) · Macular Edema
Intravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy.
Finger PT, Mukkamala SK · Eur J Ophthalmol · 2012 · Background
PubMed: PMID 21218391 · NCT03085784 (ARRT)
Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy.
Finger PT, Chin KJ · Int J Radiat Oncol Biol Phys · 2012 · Background
PubMed: PMID 21277107 · NCT03085784 (ARRT)
Corneal penetration of topical and subconjunctival bevacizumab.
Dastjerdi MH, Sadrai Z, Saban DR, et al. · Invest Ophthalmol Vis Sci · 2012 · Background
PubMed: PMID 22003112 · NCT02797704 · Corneal Neovascularization
Corneal neovascularization: an anti-VEGF therapy review.
Chang JH, Garg NK, Lunde E, et al. · Surv Ophthalmol · 2012 · Background
PubMed: PMID 22898649 · NCT01868360 · Neovascularization, Pathologic
Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
Browning DJ, Kaiser PK, Rosenfeld PJ, et al. · Am J Ophthalmol · 2012 · Background
PubMed: PMID 22813448 · NCT01971190 · Central Serous Chorioretinopathy
Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
Boyer D, Heier J, Brown DM, et al. · Ophthalmology · 2012 · Background
PubMed: PMID 22440275 · NCT01870427 (NEWTON) · Macular Edema
Aflibercept (eylea) for age-related macular degeneration.
Med Lett Drugs Ther · 2012 · Background
PubMed: PMID 22354219 · NCT01543568 (TURF) · Macular Degeneration

2011 (22 papers)

The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
Habot-Wilner Z, Barequet IS, Ivanir Y, et al. · Acta Ophthalmol · 2011 · Trial result
PubMed: PMID 19549103 · NCT02797704 · Corneal Neovascularization
The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. · Ophthalmology · 2011 · Trial result
PubMed: PMID 21546089 · NCT02556723 · Macular Degeneration
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.
de Groot JF, Piao Y, Tran H, et al. · Clin Cancer Res · 2011 · Derived
PubMed: PMID 21632852 · NCT00369590 · Astrocytoma
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Coleman RL, Duska LR, Ramirez PT, et al. · Lancet Oncol · 2011 · Derived
PubMed: PMID 21992853 · NCT00436501 · Carcinoma, Ovarian Epithelial
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Seymour MT, Thompson LC, Wasan HS, et al. · Lancet · 2011 · Background
PubMed: PMID 21570111 · NCT03530267 (ELDERLY) · Colorectal Neoplasms
Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.
Rocher N, Behar-Cohen F, Pournaras JA, et al. · Mol Vis · 2011 · Background
PubMed: PMID 21245949 · NCT02797704 · Corneal Neovascularization
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
Mitchell P, Bandello F, Schmidt-Erfurth U, et al. · Ophthalmology · 2011 · Background
PubMed: PMID 21459215 · NCT02788877 (VIBIM) · Macular Edema
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy.
Min L, Vaidya A, Becker C, et al. · Eur J Endocrinol · 2011 · Background
PubMed: PMID 21088057 · NCT04311606 (AcTED) · Graves Ophthalmopathy
Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study.
Mazhar K, Varma R, Choudhury F, et al. · Ophthalmology · 2011 · Background
PubMed: PMID 21035872 · NCT04708145 (VOYAGE) · Diabetic Retinopathy
The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy.
Lim JW, Kim MU · Graefes Arch Clin Exp Ophthalmol · 2011 · Background
PubMed: PMID 21140161 · NCT01971190 · Central Serous Chorioretinopathy
Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy.
Lee JY, Chae JB, Yang SJ, et al. · Acta Ophthalmol · 2011 · Background
PubMed: PMID 20346078 · NCT01971190 · Central Serous Chorioretinopathy
Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS.
Kozak I, Oster SF, Cortes MA, et al. · Ophthalmology · 2011 · Background
PubMed: PMID 21269701 · NCT03651011 (NIRVANA) · Macular Edema
Fundus autofluorescence and visual acuity in central serous chorioretinopathy.
Imamura Y, Fujiwara T, Spaide RF, et al. · Ophthalmology · 2011 · Background
PubMed: PMID 21055816 · NCT01543568 (TURF) · Macular Degeneration
Hallmarks of cancer: the next generation.
Hanahan D, Weinberg RA · Cell · 2011 · Background
PubMed: PMID 21376230 · NCT02192541 · Neoplasms
Protein delivery for retinal diseases: from basic considerations to clinical applications.
El Sanharawi M, Kowalczuk L, Touchard E, et al. · Prog Retin Eye Res · 2011 · Background
PubMed: PMID 20398784 · NCT04288232
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
de Groot JF, Lamborn KR, Chang SM, et al. · J Clin Oncol · 2011 · Background
PubMed: PMID 21606416 · NCT00369590 · Astrocytoma
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
CATT Research Group, Martin DF, Maguire MG, et al. · N Engl J Med · 2011 · Background
PubMed: PMID 21526923 · NCT02788877 (VIBIM) · Macular Edema
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
Campochiaro PA, Brown DM, Awh CC, et al. · Ophthalmology · 2011 · Background
PubMed: PMID 21715011 · NCT01870427 (NEWTON) · Macular Edema
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
Brown DM, Campochiaro PA, Bhisitkul RB, et al. · Ophthalmology · 2011 · Background
PubMed: PMID 21684606 · NCT03651011 (NIRVANA) · Macular Edema
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.
Bonnetain F, Dahan L, Maillard E, et al. · Eur J Cancer · 2011 · Background
PubMed: PMID 20724140 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
Bae SH, Heo JW, Kim C, et al. · Am J Ophthalmol · 2011 · Background
PubMed: PMID 21742303 · NCT01971190 · Central Serous Chorioretinopathy
Subretinal hemorrhage after photodynamic therapy for juxtapapillary retinal capillary hemangioma.
Baba T, Kitahashi M, Kubota-Taniai M, et al. · Case Rep Ophthalmol · 2011 · Background
PubMed: PMID 21589848 · NCT01714115

2010 (18 papers)

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.
Tew WP, Gordon M, Murren J, et al. · Clin Cancer Res · 2010 · Trial result
PubMed: PMID 20028764 · NCT00045266 · Lymphoma, Non-Hodgkin
Global estimates of the prevalence of diabetes for 2010 and 2030.
Shaw JE, Sicree RA, Zimmet PZ, et al. · Diabetes Res Clin Pract · 2010 · Trial result
PubMed: PMID 19896746 · NCT02556723 · Macular Degeneration
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study.
Nguyen QD, Shah SM, Khwaja AA, et al. · Ophthalmology · 2010 · Trial result
PubMed: PMID 20855114 · NCT02556723 · Macular Degeneration
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
Lockhart AC, Rothenberg ML, Dupont J, et al. · J Clin Oncol · 2010 · Trial result
PubMed: PMID 19949018 · NCT00083213 · Neoplasms
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Leighl NB, Raez LE, Besse B, et al. · J Thorac Oncol · 2010 · Trial result
PubMed: PMID 20593550 · NCT00284141 · Neoplasm Metastasis
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. · Ophthalmology · 2010 · Trial result
PubMed: PMID 20427088 · NCT04288232
Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
Avisar I, Weinberger D, Kremer I, et al. · Curr Eye Res · 2010 · Trial result
PubMed: PMID 20136420 · NCT02797704 · Corneal Neovascularization
Prevalence of diabetic retinopathy in the United States, 2005-2008.
Zhang X, Saaddine JB, Chou CF, et al. · JAMA · 2010 · Background
PubMed: PMID 20699456 · NCT04288232
Prevalence of diabetes among men and women in China.
Yang W, Lu J, Weng J, et al. · N Engl J Med · 2010 · Background
PubMed: PMID 20335585 · NCT04288232
The prevalence of retinopathy in men with Type 2 diabetes and obstructive sleep apnoea.
West SD, Groves DC, Lipinski HJ, et al. · Diabet Med · 2010 · Background
PubMed: PMID 20536514 · NCT03597815 (DME-OSA) · Sleep Apnea Syndromes
Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.
Stangos AN, Gandhi JS, Nair-Sahni J, et al. · Am J Ophthalmol · 2010 · Background
PubMed: PMID 20719300 · NCT01950741 (VAULT) · Polypoidal Choroidal Vasculopathy
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M, Price TJ, Cervantes A, et al. · J Clin Oncol · 2010 · Background
PubMed: PMID 20921462 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
VEGF Trap(R1R2) suppresses experimental corneal angiogenesis.
Oliveira HB, Sakimoto T, Javier JA, et al. · Eur J Ophthalmol · 2010 · Background
PubMed: PMID 19882518 · NCT02797704 · Corneal Neovascularization
Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma.
Mennel S, Meyer CH, Callizo J, et al. · Acta Ophthalmol · 2010 · Background
PubMed: PMID 19222401 · NCT01714115
Changes in diabetic macular oedema after phacoemulsification surgery.
Hayashi K, Igarashi C, Hirata A, et al. · Eye (Lond) · 2010 · Background
PubMed: PMID 17962820 · NCT03832179 (STAMP) · Cataract
A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact.
Gupta OP, Shienbaum G, Patel AH, et al. · Ophthalmology · 2010 · Background
PubMed: PMID 20591490 · NCT02788877 (VIBIM) · Macular Edema
Intravitreous ranibizumab (lucentis) for radiation maculopathy.
Finger PT, Chin KJ · Arch Ophthalmol · 2010 · Background
PubMed: PMID 20142553 · NCT03085784 (ARRT)
Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR.
Bressler NM, Chang TS, Suñer IJ, et al. · Ophthalmology · 2010 · Background
PubMed: PMID 20189654 · NCT06610747 (DME HOME) · Diabetic Retinopathy

2009 (16 papers)

The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes.
Klein R, Knudtson MD, Lee KE, et al. · Ophthalmology · 2009 · Trial result
PubMed: PMID 19167079 · NCT02556723 · Macular Degeneration
Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma.
Kitnarong N, Chindasub P, Metheetrairut A, et al. · Adv Ther · 2009 · Trial result
PubMed: PMID 18425438 · NCT04970251 · Glaucoma, Neovascular
"Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
Engelbert M, Zweifel SA, Freund KB, et al. · Retina · 2009 · Trial result
PubMed: PMID 19898180 · NCT04655482
Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.
Dratviman-Storobinsky O, Avraham-Lubin BCR, Hasanreisoglu M, et al. · Mol Vis · 2009 · Trial result
PubMed: PMID 19936307 · NCT02797704 · Corneal Neovascularization
Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF, Sanchez JG, Wu L, et al. · Ophthalmology · 2009 · Trial result
PubMed: PMID 19545900 · NCT04288232
Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.
Arevalo JF, Sanchez JG, Fromow-Guerra J, et al. · Graefes Arch Clin Exp Ophthalmol · 2009 · Trial result
PubMed: PMID 19189118 · NCT02556723 · Macular Degeneration
Treatment of radiation retinopathy following plaque brachytherapy for choroidal melanoma.
Wen JC, McCannel TA · Curr Opin Ophthalmol · 2009 · Background
PubMed: PMID 19349865 · NCT01579760 · Macular Edema
Prevalence of diabetic retinopathy in rural China: the Handan Eye Study.
Wang FH, Liang YB, Zhang F, et al. · Ophthalmology · 2009 · Background
PubMed: PMID 19168222 · NCT04288232
Relationship between diabetic retinopathy and sleep-disordered breathing.
Shiba T, Sato Y, Takahashi M, et al. · Am J Ophthalmol · 2009 · Background
PubMed: PMID 19268888 · NCT03597815 (DME-OSA) · Sleep Apnea Syndromes
Vascular endothelial growth factor Trap-Eye for diabetic macular oedema.
Kaiser PK · Br J Ophthalmol · 2009 · Background
PubMed: PMID 19174397 · NCT01543568 (TURF) · Macular Degeneration
Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus.
Hartnett ME, Tinkham N, Paynter L, et al. · Am J Ophthalmol · 2009 · Background
PubMed: PMID 19837384 · NCT03832179 (STAMP) · Cataract
Retinal vessel calibre and micro- and macrovascular complications in type 1 diabetes.
Grauslund J, Hodgson L, Kawasaki R, et al. · Diabetologia · 2009 · Background
PubMed: PMID 19618163 · NCT03651011 (NIRVANA) · Macular Edema
Obstructive sleep apnea among obese patients with type 2 diabetes.
Foster GD, Sanders MH, Millman R, et al. · Diabetes Care · 2009 · Background
PubMed: PMID 19279303 · NCT03597815 (DME-OSA) · Sleep Apnea Syndromes
Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study.
Cheema RA, Al-Mubarak MM, Amin YM, et al. · J Cataract Refract Surg · 2009 · Background
PubMed: PMID 19101420 · NCT07301775 · Diabetic Retinopathy
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC, Tournigand C, André T, et al. · Ann Oncol · 2009 · Background
PubMed: PMID 19153116 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Diabetic macular edema: pathogenesis and treatment.
Bhagat N, Grigorian RA, Tutela A, et al. · Surv Ophthalmol · 2009 · Background
PubMed: PMID 19171208 · NCT04288232

2008 (11 papers)

Predicted biological activity of intravitreal VEGF Trap.
Stewart MW, Rosenfeld PJ · Br J Ophthalmol · 2008 · Trial result
PubMed: PMID 18356264 · NCT03313401 · Macular Degeneration
Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation.
Freund KB, Ho IV, Barbazetto IA, et al. · Retina · 2008 · Trial result
PubMed: PMID 18301024 · NCT04655482
Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ, Margaritis LH, Voutsinas GE, et al. · Curr Med Chem · 2008 · Background
PubMed: PMID 18220746 · NCT02192541 · Neoplasms
Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050.
Saaddine JB, Honeycutt AA, Narayan KM, et al. · Arch Ophthalmol · 2008 · Background
PubMed: PMID 19064858 · NCT02299336
The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study.
Klein R, Moss SE, Meuer SM, et al. · Arch Ophthalmol · 2008 · Background
PubMed: PMID 18413521 · NCT03651011 (NIRVANA) · Macular Edema
Early macular morphological changes following plaque radiotherapy for uveal melanoma.
Horgan N, Shields CL, Mashayekhi A, et al. · Retina · 2008 · Background
PubMed: PMID 18301032 · NCT01579760 · Macular Edema
Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin).
Gupta A, Muecke JS · Retina · 2008 · Background
PubMed: PMID 18698298 · NCT03085784 (ARRT)
Intravitreal steroids for macular edema in diabetes.
Grover D, Li TJ, Chong CC, et al. · Cochrane Database Syst Rev · 2008 · Background
PubMed: PMID 18254088 · NCT02299336
Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin).
Finger PT · Int J Radiat Oncol Biol Phys · 2008 · Background
PubMed: PMID 18313522 · NCT03085784 (ARRT)
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
Blazer DG, Kishi Y, Maru DM, et al. · J Clin Oncol · 2008 · Background
PubMed: PMID 18936472 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group.
Arevalo JF, Garcia-Amaris RA, Roca JA, et al. · J Cataract Refract Surg · 2008 · Background
PubMed: PMID 18053911 · NCT03396861 (ACME) · Macular Edema

2007 (9 papers)

Evaluation of costs for cystoid macular edema among patients after cataract surgery.
Schmier JK, Halpern MT, Covert DW, et al. · Retina · 2007 · Background
PubMed: PMID 17558326 · NCT03832179 (STAMP) · Cataract
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Rubbia-Brandt L, Giostra E, Brezault C, et al. · Ann Oncol · 2007 · Background
PubMed: PMID 17060484 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.
Nguyen QD, Tatlipinar S, Shah SM, et al. · Am J Ophthalmol · 2007 · Background
PubMed: PMID 17046701 · NCT04288232
Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma.
Mason JO, Albert MA, Persaud TO, et al. · Retina · 2007 · Background
PubMed: PMID 17891015 · NCT03085784 (ARRT)
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE, Lalwani GA, Rosenfeld PJ, et al. · Am J Ophthalmol · 2007 · Background
PubMed: PMID 17386270 · NCT01543568 (TURF) · Macular Degeneration
Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review.
Fong DS, Girach A, Boney A, et al. · Retina · 2007 · Background
PubMed: PMID 17891003 · NCT03531294 · Diabetic Retinopathy
Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy.
Finger PT, Chin K · Arch Ophthalmol · 2007 · Background
PubMed: PMID 17562985 · NCT03085784 (ARRT)
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
Bock F, Onderka J, Dietrich T, et al. · Invest Ophthalmol Vis Sci · 2007 · Background
PubMed: PMID 17525183 · NCT04311606 (AcTED) · Graves Ophthalmopathy
Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).
Azar DT · Trans Am Ophthalmol Soc · 2007 · Background
PubMed: PMID 17471348 · NCT02797704 · Corneal Neovascularization

2006 (14 papers)

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).
Stratton IM, Cull CA, Adler AI, et al. · Diabetologia · 2006 · Trial result
PubMed: PMID 16736131 · NCT02556723 · Macular Degeneration
Ranibizumab: Phase III clinical trial results.
Rosenfeld PJ, Rich RM, Lalwani GA, et al. · Ophthalmol Clin North Am · 2006 · Trial result
PubMed: PMID 16935211 · NCT02291887 · Macular Degeneration
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Rosenfeld PJ, Heier JS, Hantsbarger G, et al. · Ophthalmology · 2006 · Trial result
PubMed: PMID 16581423 · NCT02291887 · Macular Degeneration
Promising new treatments for neovascular age-related macular degeneration.
Michels S, Schmidt-Erfurth U, Rosenfeld PJ, et al. · Expert Opin Investig Drugs · 2006 · Trial result
PubMed: PMID 16787141 · NCT02291887 · Macular Degeneration
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Heier JS, Antoszyk AN, Pavan PR, et al. · Ophthalmology · 2006 · Trial result
PubMed: PMID 16483659 · NCT02291887 · Macular Degeneration
Dynamics of retinal function after multiple photodynamic therapies in age-related macular degeneration: a report of cases.
Feigl B, Brown B, Lovie-Kitchin J, et al. · Doc Ophthalmol · 2006 · Trial result
PubMed: PMID 16523231 · NCT02291887 · Macular Degeneration
Ranibizumab for neovascular age-related macular degeneration.
Rosenfeld PJ, Brown DM, Heier JS, et al. · N Engl J Med · 2006 · Background
PubMed: PMID 17021318 · NCT01950741 (VAULT) · Polypoidal Choroidal Vasculopathy
Association of sleep apnea and type II diabetes: a population-based study.
Reichmuth KJ, Austin D, Skatrud JB, et al. · Am J Respir Crit Care Med · 2006 · Background
PubMed: PMID 16192452 · NCT03597815 (DME-OSA) · Sleep Apnea Syndromes
Diabetic cataract removal: postoperative progression of maculopathy--growth factor and clinical analysis.
Patel JI, Hykin PG, Cree IA, et al. · Br J Ophthalmol · 2006 · Background
PubMed: PMID 16540489 · NCT03832179 (STAMP) · Cataract
Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion.
Noma H, Minamoto A, Funatsu H, et al. · Graefes Arch Clin Exp Ophthalmol · 2006 · Background
PubMed: PMID 16133018 · NCT03651011 (NIRVANA) · Macular Edema
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Mabro M, Artru P, André T, et al. · Br J Cancer · 2006 · Background
PubMed: PMID 16622455 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation.
Cursiefen C, Maruyama K, Jackson DG, et al. · Cornea · 2006 · Background
PubMed: PMID 16670483 · NCT04311606 (AcTED) · Graves Ophthalmopathy
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
Brown DM, Kaiser PK, Michels M, et al. · N Engl J Med · 2006 · Background
PubMed: PMID 17021319 · NCT01543568 (TURF) · Macular Degeneration
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL, Pieramici DJ, Rabena MD, et al. · Ophthalmology · 2006 · Background
PubMed: PMID 16458968 · NCT01543568 (TURF) · Macular Degeneration

2005 (8 papers)

Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation.
Gross NE, Aizman A, Brucker A, et al. · Retina · 2005 · Trial result
PubMed: PMID 16141858 · NCT04655482
Vascular endothelial growth factor: basic science and clinical progress.
Ferrara N · Endocr Rev · 2005 · Trial result
PubMed: PMID 15294883 · NCT02556723 · Macular Degeneration
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
Cunningham ET, Adamis AP, Altaweel M, et al. · Ophthalmology · 2005 · Trial result
PubMed: PMID 16154196 · NCT02556723 · Macular Degeneration
Choroidal neovascularisation in pathological myopia: an update in management.
Chan WM, Ohji M, Lai TY, et al. · Br J Ophthalmol · 2005 · Trial result
PubMed: PMID 16234465 · NCT04290195
The origins of polypoidal choroidal vasculopathy.
Yuzawa M, Mori R, Kawamura A, et al. · Br J Ophthalmol · 2005 · Background
PubMed: PMID 15834093 · NCT04075188 · Choroidal Neovascularization
Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Rosenfeld PJ, Moshfeghi AA, Puliafito CA, et al. · Ophthalmic Surg Lasers Imaging · 2005 · Background
PubMed: PMID 16156152 · NCT01543568 (TURF) · Macular Degeneration
Periocular routes for retinal drug delivery.
Raghava S, Hammond M, Kompella UB, et al. · Expert Opin Drug Deliv · 2005 · Background
PubMed: PMID 16296723 · NCT03396861 (ACME) · Macular Edema
Pegaptanib for neovascular age-related macular degeneration.
Gragoudas ES, Adamis AP, Cunningham ET, et al. · N Engl J Med · 2005 · Background
PubMed: PMID 15625332 · NCT01543568 (TURF) · Macular Degeneration

2004 (8 papers)

Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy.
Wong R, Chopdar A, Brown M, et al. · Eye (Lond) · 2004 · Background
PubMed: PMID 15004575 · NCT01971190 · Central Serous Chorioretinopathy
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Tournigand C, André T, Achille E, et al. · J Clin Oncol · 2004 · Background
PubMed: PMID 14657227 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Mabro M, Louvet C, André T, et al. · Am J Clin Oncol · 2004 · Background
PubMed: PMID 12796595 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
The prevalence of diabetic retinopathy among adults in the United States.
Kempen JH, O'Colmain BJ, Leske MC, et al. · Arch Ophthalmol · 2004 · Background
PubMed: PMID 15078674 · NCT04708145 (VOYAGE) · Diabetic Retinopathy
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Hurwitz H, Fehrenbacher L, Novotny W, et al. · N Engl J Med · 2004 · Background
PubMed: PMID 15175435 · NCT02045030 · Colorectal Neoplasms
Prevalence of age-related macular degeneration in the United States.
Friedman DS, O'Colmain BJ, Muñoz B, et al. · Arch Ophthalmol · 2004 · Background
PubMed: PMID 15078675 · NCT05710471 · Macular Degeneration
Causes and prevalence of visual impairment among adults in the United States.
Congdon N, O'Colmain B, Klaver CC, et al. · Arch Ophthalmol · 2004 · Background
PubMed: PMID 15078664 · NCT03022292 (IAI-OCTA) · Wet Macular Degeneration
Age-related macular degeneration is the leading cause of blindness..
Bressler NM · JAMA · 2004 · Background
PubMed: PMID 15108691 · NCT05710471 · Macular Degeneration

2003 (8 papers)

VEGF164 is proinflammatory in the diabetic retina.
Ishida S, Usui T, Yamashiro K, et al. · Invest Ophthalmol Vis Sci · 2003 · Trial result
PubMed: PMID 12714656 · NCT02556723 · Macular Degeneration
Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.
Eyetech Study Group · Ophthalmology · 2003 · Trial result
PubMed: PMID 12750101 · NCT02291887 · Macular Degeneration
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.
Wilkinson CP, Ferris FL, Klein RE, et al. · Ophthalmology · 2003 · Background
PubMed: PMID 13129861 · NCT07301775 · Diabetic Retinopathy
Diabetes and sleep disturbances: findings from the Sleep Heart Health Study.
Resnick HE, Redline S, Shahar E, et al. · Diabetes Care · 2003 · Background
PubMed: PMID 12610025 · NCT03597815 (DME-OSA) · Sleep Apnea Syndromes
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization.
Rakic JM, Lambert V, Devy L, et al. · Invest Ophthalmol Vis Sci · 2003 · Background
PubMed: PMID 12824270 · NCT02559180 (SwapTwo) · Diabetic Retinopathy
Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.
Nagy JA, Vasile E, Feng D, et al. · J Exp Med · 2003 · Background
PubMed: PMID 12461084 · NCT04311606 (AcTED) · Graves Ophthalmopathy
Cystoid macular degeneration in chronic central serous chorioretinopathy.
Iida T, Yannuzzi LA, Spaide RF, et al. · Retina · 2003 · Background
PubMed: PMID 12652224 · NCT01543568 (TURF) · Macular Degeneration
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.
Beer PM, Bakri SJ, Singh RJ, et al. · Ophthalmology · 2003 · Background
PubMed: PMID 12689886 · NCT06662994 · Diabetic Retinopathy

2002 (7 papers)

Retinal angiomatous proliferation in age-related macular degeneration.
Yannuzzi LA, Negrão S, Iida T, et al. · Retina · 2002 · Trial result
PubMed: PMID 11642370 · NCT04655482
VEGF-Trap: a VEGF blocker with potent antitumor effects.
Holash J, Davis S, Papadopoulos N, et al. · Proc Natl Acad Sci U S A · 2002 · Trial result
PubMed: PMID 12177445 · NCT02556723 · Macular Degeneration
Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63).
Gray A, Clarke P, Farmer A, et al. · BMJ · 2002 · Trial result
PubMed: PMID 12386035 · NCT02556723 · Macular Degeneration
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19.
Jampol LM, Moy CS, Murray TG, et al. · Ophthalmology · 2002 · Background
PubMed: PMID 12466159 · NCT03085784 (ARRT)
Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group · Retina · 2002 · Background
PubMed: PMID 11927845 · NCT01543568 (TURF) · Macular Degeneration
[Pathogenesis of central serous chorioretinopathy: angiographic and electrophysiological studies].
Dohrmann J, Lommatzsch A, Spital G, et al. · Ophthalmologe · 2002 · Background
PubMed: PMID 11729739 · NCT01971190 · Central Serous Chorioretinopathy
Effect of cataract surgery on the progression of diabetic retinopathy.
Chung J, Kim MY, Kim HS, et al. · J Cataract Refract Surg · 2002 · Background
PubMed: PMID 11955902 · NCT07301775 · Diabetic Retinopathy

2001 (5 papers)

Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16.
Melia BM, Abramson DH, Albert DM, et al. · Ophthalmology · 2001 · Background
PubMed: PMID 11158813 · NCT03085784 (ARRT)
How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy.
Klein R, Klein BE, Moss SE, et al. · Arch Ophthalmol · 2001 · Background
PubMed: PMID 11296020 · NCT04708145 (VOYAGE) · Diabetic Retinopathy
VEGF: an update on biological and therapeutic aspects.
Ferrara N · Curr Opin Biotechnol · 2001 · Background
PubMed: PMID 11102799 · NCT02299336
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Falcone A, Di Paolo A, Masi G, et al. · J Clin Oncol · 2001 · Background
PubMed: PMID 11481350 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Corneal neovascularization.
Chang JH, Gabison EE, Kato T, et al. · Curr Opin Ophthalmol · 2001 · Background
PubMed: PMID 11507336 · NCT02797704 · Corneal Neovascularization

2000 (2 papers)

Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
Mans DR, Grivicich I, Peters GJ, et al. · Eur J Cancer · 2000 · Background
PubMed: PMID 10674003 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Vascular endothelial growth factor and the regulation of angiogenesis.
Ferrara N · Recent Prog Horm Res · 2000 · Background
PubMed: PMID 11036931 · NCT02503540 (PERMEATE) · Macular Edema

1999 (2 papers)

Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions.
Thickett DR, Armstrong L, Millar AB, et al. · Thorax · 1999 · Background
PubMed: PMID 10413724 · NCT02503540 (PERMEATE) · Macular Edema
Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma.
Gündüz K, Shields CL, Shields JA, et al. · Arch Ophthalmol · 1999 · Background
PubMed: PMID 10326957 · NCT03085784 (ARRT)

1998 (3 papers)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet · 1998 · Trial result
PubMed: PMID 9742976 · NCT02556723 · Macular Degeneration
Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
Mullany S, Svingen PA, Kaufmann SH, et al. · Cancer Chemother Pharmacol · 1998 · Background
PubMed: PMID 9771954 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
The 14-year incidence of visual loss in a diabetic population.
Moss SE, Klein R, Klein BE, et al. · Ophthalmology · 1998 · Background
PubMed: PMID 9627648 · NCT04288232

1997 (3 papers)

Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.
Guichard S, Cussac D, Hennebelle I, et al. · Int J Cancer · 1997 · Background
PubMed: PMID 9398054 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis
Early photocoagulation in patients with either type I or type II diabetes.
Ferris F · Trans Am Ophthalmol Soc · 1997 · Background
PubMed: PMID 8981711 · NCT02863354 (RECOVERY)
The biology of vascular endothelial growth factor.
Ferrara N, Davis-Smyth T · Endocr Rev · 1997 · Background
PubMed: PMID 9034784 · NCT02559180 (SwapTwo) · Diabetic Retinopathy

1996 (1 paper)

Indocyanine green videoangiography of older patients with central serous chorioretinopathy.
Spaide RF, Hall L, Haas A, et al. · Retina · 1996 · Background
PubMed: PMID 8789858 · NCT01971190 · Central Serous Chorioretinopathy

1995 (1 paper)

Role of leucovorin dosing and administration schedule.
Jolivet J · Eur J Cancer · 1995 · Background
PubMed: PMID 7577042 · NCT04392479 (TWICE-IRI) · Neoplasm Metastasis

1994 (3 papers)

Diseases of the retina.
D'Amico DJ · N Engl J Med · 1994 · Trial result
PubMed: PMID 8208273 · NCT02291887 · Macular Degeneration
Ten-year incidence of visual loss in a diabetic population.
Moss SE, Klein R, Klein BE, et al. · Ophthalmology · 1994 · Background
PubMed: PMID 8008348 · NCT04288232
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
Aiello LP, Avery RL, Arrigg PG, et al. · N Engl J Med · 1994 · Background
PubMed: PMID 7526212 · NCT03651011 (NIRVANA) · Macular Edema

1993 (1 paper)

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. · N Engl J Med · 1993 · Trial result
PubMed: PMID 8366922 · NCT02556723 · Macular Degeneration

1992 (3 papers)

The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group.
Arch Ophthalmol · 1992 · Background
PubMed: PMID 1417537 · NCT01868360 · Neovascularization, Pathologic
The vascular endothelial growth factor family of polypeptides.
Ferrara N, Houck KA, Jakeman LB, et al. · J Cell Biochem · 1992 · Background
PubMed: PMID 1791185 · NCT02559180 (SwapTwo) · Diabetic Retinopathy
Continued breakdown of the blood aqueous barrier following cataract surgery.
Ferguson VM, Spalton DJ · Br J Ophthalmol · 1992 · Background
PubMed: PMID 1390524 · NCT03832179 (STAMP) · Cataract

1991 (3 papers)

Progression of diabetic retinopathy after cataract extraction.
Pollack A, Dotan S, Oliver M, et al. · Br J Ophthalmol · 1991 · Background
PubMed: PMID 1911658 · NCT07301775 · Diabetic Retinopathy
Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.
Ophthalmology · 1991 · Background
PubMed: PMID 2062515 · NCT03531294 · Diabetic Retinopathy
Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.
Ophthalmology · 1991 · Background
PubMed: PMID 2062512 · NCT02863354 (RECOVERY)

1989 (1 paper)

Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.
Mourits MP, Koornneef L, Wiersinga WM, et al. · Br J Ophthalmol · 1989 · Background
PubMed: PMID 2765444 · NCT04311606 (AcTED) · Graves Ophthalmopathy

1988 (1 paper)

Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group.
Int Ophthalmol Clin · 1988 · Background
PubMed: PMID 3692707 · NCT03651011 (NIRVANA) · Macular Edema

1986 (2 papers)

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.
Arch Ophthalmol · 1986 · Background
PubMed: PMID 2866759 · NCT02299336
Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group.
Arch Ophthalmol · 1986 · Background
PubMed: PMID 2417579 · NCT03651011 (NIRVANA) · Macular Edema

1985 (2 papers)

A population-based study of diabetic retinopathy in insulin-using patients diagnosed before 30 years of age.
Klein R, Klein BE, Moss SE, et al. · Diabetes Care · 1985 · Background
PubMed: PMID 4053957 · NCT03531294 · Diabetic Retinopathy
The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema.
Klein R, Klein BE, Moss SE, et al. · Ophthalmology · 1985 · Background
PubMed: PMID 6521986 · NCT02299336

1984 (1 paper)

The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.
Klein R, Klein BE, Moss SE, et al. · Arch Ophthalmol · 1984 · Background
PubMed: PMID 6367725 · NCT04288232

1981 (1 paper)

Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group.
Ophthalmology · 1981 · Background
PubMed: PMID 7196564 · NCT02863354 (RECOVERY)

1976 (1 paper)

Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group.
Am J Ophthalmol · 1976 · Background
PubMed: PMID 944535 · NCT02863354 (RECOVERY)

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Thu, 14 May 2026 21:39:09 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).